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ABSTRACT 
 
Accelerating Coagulation in Traumatic Injuries Using Inorganic Nanoparticles 
 
by 
 
Damien Kudela 
 
Trauma remains the leading cause of mortality between the ages of 1 and 44 in the 
United States. Uncontrolled blood loss accounts for 50 % of all battlefield deaths and up to 
25 % of civilian trauma deaths. This mortality is often the result of a severe clotting 
impairment known as acute traumatic coagulopathy. Therefore, hemorrhage control remains 
the a priori goal in the care of the critically injured patient.  While great advances have been 
made in the resuscitation of the injured patient, attenuating bleeding and correction of 
coagulopathy remain vexing clinical problems. Current clotting treatments are plagued by 
concerns over excessive cost, poor stability, and safety issues. 
In this defense, I present a silica nanoparticle (SNP) functionalized with 
polyphosphate (polyP) that mediates the body’s natural clotting process. SNPs initiate the 
blood clotting system’s contact pathway, while the endogenous short-chain polyP accelerates 
the common pathway via rapid formation of thrombin. This enhances the overall blood-
clotting system, both by accelerating fibrin generation and by facilitating the regulatory 
anticoagulation mechanisms essential for hemostasis. Because of its low production cost, 
long-term stability at ambient conditions, and the potential to minimize side effects seen in 
 ix 
 
current treatments, the polyP-SNP therapeutic has the possibility to enable the body to re-
establish hemostasis after traumatic injury, preventing massive blood loss and saving lives. 
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I. Trauma 
Midway upon the journey of our life 
I found myself within a forest dark, 
For the straightforward pathway had been lost. 
 
Ah me! how hard a thing it is to say 
What was this forest savage, rough, and stern, 
Which in the very thought renews the fear. 
 
So bitter is it, death is little more; 
But of the good to treat, which there I found, 
Speak will I of the other things I saw there. 
 
I cannot well repeat how there I entered, 
So full was I of slumber at the moment 
In which I had abandoned the true way. 
- Dante Aligheiri, Inferno, Canto I, 1-12 
 
A. Introduction  
Hemorrhage control remains the a priori goal in the care of the critically injured patient. 
Uncontrolled blood loss accounts for up to 25 % of civilian trauma deaths and over 50 % of 
all battlefield deaths.(1-6) Within the first 48 hours after injury, hemorrhage causes the 
majority of trauma deaths (Figure 1).(7, 8) Current treatment calls for rapid transport to 
hospital for large volume resuscitation and surgical intervention to stem the loss of blood and 
continued resuscitation. Hemostatic resuscitation practices include aggressive blood product 
resuscitation rapid interventions, limited crystalloid infusion, surgical techniques to stem 
blood loss, and hemostatic adjuncts.(9, 10)  
When a blood vessel is injured, the escaping blood comes into contact with tissue factor 
(TF) to initiate the extrinsic, or tissue factor, pathway of blood clotting (Figure 2). The 
extrinsic pathway is the biologically dominant mechanism for initiating coagulation in 
humans. F(actor) VII in the blood becomes activated (FVIIa) and binds with TF to form the 
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TF-FVIIa complex. Once complexed, TF-FVIIa accelerate activation of downstream FIXa 
and FXa. At the end of the tissue factor pathway, small concentrations of prothrombin are 
cleaved to produce thrombin.(11) 
In addition to the extrinsic pathway, blood clotting can initiate via FXII and the intrinsic 
pathway through autoactivation or the introduction of negatively charged surfaces such as 
silica (Figure 2).(12-14) Once activated, FXIIa complexes with prekallikrein (PK) and high-
molecular weight kininogen (HMWK) to produce larger quantities of FXIIa. In the presence 
of FXIIa, HMWK converts FXI into FXIa, which then converts FIX into FIXa.(15)  
Whether initiated intrinsically or extrinsically, the activation of FIXa and FXa signal a 
shift from initiation to the common activation, or propagation pathway. The main goal of the 
common pathway is to accelerate coagulation and regulation of the blood clotting process 
through a thrombin burst, a mass production of thrombin (Figure 2).(16) This thrombin burst 
is produced by the prothrombinase (FXa-FVa complex) rapidly converting prothrombin into 
thrombin.(11) Aided by polyphosphate, thrombin autocatalyzes FXIa,(17) FVa,(18) 
FVIIIa,(19) to strengthen the mechanism and accelerate further thrombin production.(19) In 
the final stage of coagulation, thrombin converts fibrinogen into fibrin, activates FXIIIa,(20) 
and activates platelets(11) to assist in forming the physical clot that shuts injury and prevents 
further blood loss. FXIIIa cross-links fibrin monomers into polymers that form the backbone 
for strong clots.(16)  
Because thrombin is so robustly procoagulant, it must be carefully regulated by the body. 
To prevent spread of coagulation away from the injury site, thrombin is captured by the 
surface-protein thrombomodulin (TM)(11) and inhibited by antithrombin-III (AT-III) (Figure 
2).(21) This process turns thrombin into an anticoagulant. Upon capture by TM and AT-III, 
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thrombin promotes activation of protein C (aPC, Figure 2), which regulates the clotting 
cascade(11, 22-24) to keep the clotting localized. APC also accelerates fibrinolysis, the 
breakdown of the fibrin clot, which enables the vessel to heal after injury and return to 
hemostasis.(22-24) If overexpressed, thrombin’s anticoagulant role can lead to severe 
clotting deficiencies in trauma patients.(23) 
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Figure 1. The majority of hemorrhage deaths occur within 24 hours of hospitalization. 
Reprinted from The Lancet, 376/6736, the CRASH-2 collaborators, Effects of 
tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma 
patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled 
trial, 23-32, Copyright (2010), with permission from Elsevier.(8) 
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Figure 2. Simplified coagulation cascade. Coagulation can either be initiated by the 
exposure of blood to tissue factor (TF, extrinsic pathway) or to a negatively-charged 
surface such as silica that induces the activation of FXII through intrinsic (contact 
activation) pathway. Both initiation pathways meet at the common activation pathway, 
where FXa and FVa combine to produce large quantities of thrombin. In the final step, 
fibrinogen is converted into fibrin to form the physical clot. 
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Trauma management has been influenced by combat since the dawn of humanity. As 
combat injuries tend to be more grievous and difficult to treat, advances in military medical 
care are often adapted in short order by civilian medical personnel. Hippocrates once stated, 
“He who would become a surgeon, let him join an army and follow it.” Evidence of bandages 
used to treat wounds and prevent further blood loss dates back to Homer’s Iliad. Modern 
military medicine begins with Napoleon’s chief surgeon, Dominique Jean Larrey. Larrey is 
credited with pioneering both the use of triage in treating injured soldiers as well as the 
advent of ambulances to retrieve soldiers from the battlefield and bring them to field 
hospitals.(25) 
While 15-25% of trauma deaths occur as a result of external or internal hemorrhage,(3) 
this number rises to nearly 50 % on the battlefield.(3-6) Over the past century, the killed in 
action rates for US soldiers have remained relatively stable between 20 – 25 % of all 
casualties (Figure 3).(26) However, overall combat mortality has decreased because of a 
reduction in wounded soldiers who later died of their wounds (Figure 4).(5) This reduction in 
combat mortality is a direct result of better treatment protocols aimed at preventing injured 
soldiers from subsequently dying of their wounds. In World War II, 19 % of the wounded 
soldiers died. A slightly smaller fraction, 15 % of the wounded soldiers, died in Vietnam.(4, 
5) In Iraq and Afghanistan, the US case fatality rate dropped below 9 %.(27) This significant 
decrease in case fatality rate occurred because of a revolution in trauma care that emphasized 
prehospital management to improve the condition of patients prior to arrival, thus leading to 
increased survival rates. 
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Figure 3. Percent of combat casualties killed in action from 1854-1989. Crimean War, 
1854–55 (British battle casualties); American Civil War, 1861–65 (Union); Franco-
Prussian War, 1870–71 (German); Russo-Japanese War, 1904–05 (Japanese); France 
and Flanders, 1914–18 (British); Conquest of France, 1940 (German); Russian Front, 
1942 (German); Italy, 1944–45 (American); Korean War, 1950–53 (American); 
Vietnam War, 1964–73 (U.S. Marine Corps); Northern Ireland, 1970–84 (British); 
Afghanistan War, 1979–89 (Soviet). Reprinted from The Journal of Trauma and Acute 
Care Surgery, Vol. 54, Issue 5, HR Champion, RF Bellamy, P Roberts, A Leppaniemi, 
A profile of combat injury, S13-S19, Copyright (2003), with permission from Wolters 
Kluwer Health, Inc.(5) 
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Figure 4. Percent of soldiers who died of their wounds after reaching a field hospital 
from 1854-1989. Crimean War, 1854–55 (British battle casualties); American Civil 
War, 1861–65 (Union); Franco-Prussian War, 1870–71 (German); Russo-Japanese 
War, 1904–05 (Japanese); France and Flanders, 1914–18 (British); Conquest of France, 
1940 (German); Russian Front, 1942 (German); Italy, 1944–45 (American); Korean 
War, 1950–53 (American); Vietnam War, 1964–73 (U.S. Marine Corps); Northern 
Ireland, 1970–84 (British); Afghanistan War, 1979–89 (Soviet). Reprinted from The 
Journal of Trauma and Acute Care Surgery, Vol. 54, Issue 5, HR Champion, RF 
Bellamy, P Roberts, A Leppaniemi, A profile of combat injury, S13-S19, Copyright 
(2003), with permission from Wolters Kluwer Health, Inc.(5) 
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At the onset of Operation Enduring Freedom and Operation Iraqi Freedom, combat 
medics were unprepared for the type of casualties they would face. An unacceptable 
mortality rate continued to exist in the early years of the wars in Iraq and Afghanistan, when 
potentially survivable external wound deaths made up 15-28% of all combat fatalities.(5, 28) 
Of these potentially survivable deaths, 80 % occurred due to hemorrhage.(29)  
One of the underlying reasons for increased mortality was a shift in the cause and 
location of injury. In Iraq and Afghanistan, explosions accounted for 72 % (65 % in 
Vietnam) of all injuries compared to 18 % (35 % in Vietnam) of wounds from gunshots.(30) 
The rise in injury due to non-penetrating or blunt injuries also led to an increase in internal 
injuries that are more difficult to treat due to their inaccessibility. Head and neck injuries 
made up 31 % of all casualties (16 % in Vietnam), truncal injuries rose to 27 %, (23 % in 
Vietnam), while extremity injuries fell significantly to 39 % (61 % in Vietnam).(30) As a 
result of inadequate treatment and protocols, the military needed to change trauma care 
protocols to adapt to new battlefield conditions. Spurred on by the US Special Operations 
Forces, by 2009, all six branches of the military had adopted the Tactical Combat Casualty 
Care (TCCC) guidelines for battlefield protocol in partnership with the Joint Trauma System 
(JTS) to systematically review combat casualties and their care.(28, 31)  Improving 
prehospital care became the overarching focus due to the fact that 90 % of combat fatalities 
occur prior to arrival at a medical facility.(5) The TCCC and JTS have proven successful at 
training combat medical personnel to limit compressible, extremity bleeding mortality and 
have identified the first treatment protocol, using tranexamic acid, for patients suffering 
noncompressible hemorrhage on the battlefield.(28) 
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B. Acute Coagulopathy of Trauma 
Clinicians have identified acute traumatic coagulopathy (ATC), an endogenous 
hypocoagulable state present in 25-40% of patients nearly immediately after injury.(32) ATC 
is a multifactorial process involving an endogenous hypocoagulable state occurring nearly 
immediately after injury complicated by issues such as the injury suffered, clotting 
abnormalities, cellular interaction, and inflammation (Figure 5).(33) Shock is suspected to 
instigate ATC after injury.(22)  
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Figure 5. ATC develops endogenously as a response to multiple systemic factors 
including tissue injury and hemorrhage. Reprinted from Thrombosis Research, 129(5), 
D Frith, MJ Cohen, K Brohi, Animal models of trauma-induced coagulopathy, Pages 
No. 551-556, Copyright (2012), with permission from Elsevier.(34) 
 
  
  12 
 
The onset of ATC is associated with worsened bleeding, increased need for transfusion, 
and a 4-fold increase in mortality.(33, 34) Within the first 24 hours after injury, coagulopathy 
results in an 8-fold increase in mortality.(35) This is due to a two-fold problem caused by 
coagulopathy. First, ATC leads to activation of protein C (aPC), which is the primary 
anticoagulant pathway. In the aPC pathway (Figures 6, 7), the thrombin that is produced at 
the wound site to accelerate clot formation is captured by thrombomodulin (TM) to form the 
thrombin-TM pathway.(22, 23) This converts thrombin from its main task as the key 
procoagulant in the clotting cascade(11) into a potent anticoagulant agent at the most critical 
time for the patient to clot.(22, 23)  
Adding additional insult, the injury can dislodge tissue plasminogen activator (tPA) 
production from the endothelium into the bloodstream. In ATC, the elevated levels of aPC 
and tPA accelerate fibrinolysis (Figure 7), which is the breakdown of the physical fibrin clot 
into fibrin degradation products (FDPs). Thus, at the time the body has the greatest need to 
form clots to prevent further blood loss, the body’s clotting mechanism becomes reversed. 
The protein needed to signal rapid clot formation instead initiates anti-clotting, while the 
clots that do form are quickly broken down and unable to stem the tide of blood loss.(22, 23) 
Medical treatment can exacerbate conditions and induce an iatrogenic coagulopathy through 
use of non-blood product resuscitative fluids that further deplete coagulation factors. The 
unfortunate sequelae of resuscitative efforts, iatrogenic coagulopathy, hypothermia, and 
acidosis form a ‘lethal triad’ that signal imminent mortality.(36) Therefore, it is no surprise 
that the appearance of ATC is a harbinger of mortality. 
In the first 24 hours, doctors race against time to keep the patient from exsanguinating. 
Initially, coagulopathic patients receive massive transfusions of blood products to help 
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replenish procoagulant factors that have been lost.(22, 23, 33, 34, 37) If this proves 
insufficient, doctors move next to clotting agents such as the antifibrinolytic tranexamic 
acid(8) or recombinant clotting factors.(2, 38)  
Even if the patient survives the critical first 24 hour period, grave risks other than 
hemorrhage complicate recovery. The risk for unwanted thrombotic events rises because the 
body is in a strongly hypercoagulant state to enable it to successfully clot in the presence of 
coagulopathy.(39, 40) The use of procoagulant agents to further induce clotting may raise the 
risk of thrombosis in trauma patients.(41) This results in a conundrum for doctors – how to 
treat bleeding and induce healthy clotting immediately after injury without putting the patient 
at-risk for life-threatening clots once the threat of exsanguination has passed? 
In addition to major thrombotic events such as emboli,(39) the hypercoagulable state can 
also lead to disseminated intravascular coagulation (DIC).(42) In DIC, the hypercoagulable 
state results in procoagulant factor activation throughout the body despite the absence of 
injury. The resulting microthrombi can occlude healthy vessels (Figure 8).(42) However, 
only 5 – 10 % of all DIC cases are due to microthrombi.(43) Instead, DIC usually presents in 
patients as a secondary symptom of sepsis.(43) In this scenario, the whole-body 
hypercoagulable state exhausts the body’s supply of clotting factors, leaving the patient again 
at risk for uncontrollable hemorrhage if sepsis or another condition leads to a later bleeding 
episode (Figure 8).(42) The only option for clinicians is to treat the underlying cause. Neither 
antifibrinolytics nor anticoagulants such as heparin are recommended for DIC patients as 
they can tip the precarious balancing act towards hemorrhage or thrombosis.(43) 
In addition to thrombosis, patients who survive for 24 h after the onset of ATC face 
increased risks of organ failure, infection and inflammatory complications.(33) The 
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coagulation and inflammation pathways are interconnected as the body must first clot the 
wound after injury and then repair it via inflammation to return to homeostasis.(24, 44, 45) 
While necessary, this pathway can become perturbed. aPC is the integral anti-inflammatory 
protein.(24, 45) Because ATC leads to initial elevated levels of aPC, the hypercoagulable 
post-ATC state can lead to a crash in protein C levels.(46) In conjunction with DIC, 
unchecked inflammatory responses can damage organs,(42) increase the risk for 
infection,(44) and ultimately result in sepsis,(47) thus contributing to many of the non-
hemorrhage trauma mortalities post-injury. 
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Figure 6. In ATC, thrombin binding to thrombomodulin (TM) accelerates. This 
increases activation of protein C (aPC) and leads to systemic dominance of the 
anticoagulant pathway. Reprinted from Current Opinion in Critical Care, 13(6), K 
Brohi MJ Cohen, R Davenport, Acute coagulopathy of trauma: mechanism, 
identification and effect, Pages No. 680-685, Copyright (2007), with permission from 
Wolters Kluwer Health, Inc.(22) 
  
  16 
 
 
Figure 7. Injury leads to release of tissue plasminogen activator (tPA). Activated 
protein C (aPC) and tPA accelerate fibrinolysis – the breakdown of fibrin into fibrin 
degradation products (FDPs). Reprinted from Current Opinion in Critical Care, 13(6), 
K Brohi MJ Cohen, R Davenport, Acute coagulopathy of trauma: mechanism, 
identification and effect, Pages No. 680-685, Copyright (2007), with permission from 
Wolters Kluwer Health, Inc.(22)  
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Figure 8. The hypercoagulable state that develops in response to ATC can lead to 
disseminated intravascular coagulation - a systemic activation of coagulation – that can 
cause two fatal conditions. Reproduced with permission from Levi M & ten Cate H 
(1999) Disseminated intravascular coagulation. New England Journal of Medicine 
341(8):586-592, Copyright Massachusetts Medical Society.(42) 
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C. Blood Products 
The use of blood transfusion to replace shed blood dates back to the First World War.(48) 
At the outset of the Second World War, US military medicine relied on freeze-dried plasma 
due to its ease of production, storage, and use.(48) Freeze-dried plasma was abandoned in 
favor of whole blood because it was ineffective in patients who went into shock.(49) Civilian 
blood banks were set up to answer this need, with 2,000 units of blood supplied per day to 
Europe and the Pacific in March 1945.(48) In Korea, guidelines dictated transfusing more 
whole blood than was lost as opposed to a 1:1 ratio in previous wars.(49) By the 1980s, 
whole blood transfusions began to be replaced by a combination of blood products - red 
blood cells (RBCs), fresh frozen plasma (FFP), and platelets.(48)  
Severe trauma injuries often require massive transfusions – 10 or more RBC units in a 24 
hour period – to replace blood that is shed after injury.(50-53) In combat hospitals, 5 % of 
patients receive massive transfusion.(50) The mortality rate is above 30 % for those receiving 
a massive transfusion of RBCs.(54) In civilian hospitals, 1 – 3 % of patients receive a 
massive transfusion,(53, 55, 56) 15 % of the most severe trauma patients receive a massive 
transfusion,(47) and the mortality rate for this population lies between 20 – 50 %.(7, 47, 51)  
To determine the ideal transfusion protocol, varying transfusion ratios of blood products 
were tested (Figures 9, 10).(50) Researchers concluded that clinicians should aim for a ratio 
of  
1:1:1 FFP:platelets:RBC to greatest survival rates and survival times (Figures 9, 10).(50, 57) 
In the subsequent Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) 
trial, the 1:1:1 ratio led to a slightly reduced rate of exsanguination deaths than 1:1:2.(58) 
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Figure 9. Transfusing plasma to RBC at a 1:1.4 ratio leads to low mortality rates. 
Reprinted from The Journal of Trauma and Acute Care Surgery, Vol. 63, Issue 4, MA 
Borgman, PC Spinella, JG Perkins, KW Grathwohl, T Repine, AC Beekley, J Sebesta, 
D Jenkins, CE Wade, JB Holcomb, The Ratio of Blood Products Transfused Affects 
Mortality in Patients Receiving Massive Transfusions at a Combat Support Hospital, 
805-813, Copyright (2007), with permission from Wolters Kluwer Health, Inc.(50) 
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Figure 10. Transfusing patients with a 1:1.4 plasma:RBC ratio decreases mortality due 
to hemorrhage and increases the survival time for a patient. Reprinted from The 
Journal of Trauma and Acute Care Surgery, Vol. 63, Issue 4, MA Borgman, PC 
Spinella, JG Perkins, KW Grathwohl, T Repine, AC Beekley, J Sebesta, D Jenkins, CE 
Wade, JB Holcomb, The Ratio of Blood Products Transfused Affects Mortality in 
Patients Receiving Massive Transfusions at a Combat Support Hospital, 805-813, 
Copyright (2007), with permission from Wolters Kluwer Health, Inc.(50) 
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D. Tourniquets 
 Though preventable given quick and effective treatment, patients suffering major 
arterial bleeds can exsanguinate in minutes.(59) Prior to 2003, tourniquet use was 
discouraged to prevent long-term tissue damage in limbs such as the need for 
amputation.(59) Even proponents of tourniquets followed the words of Larrey, who stated at 
the Battle of Borodino in 1812, “Better to lose the limb and save the life”. Quantitative 
tourniquet studies on the battlefield would not be undertaken until the turn of the 20th century 
with Lakstein’s retrospective study, which showed that the use of tourniquets in 91 Israeli 
Defense Force patients had a 100 % survival rate.(60) One of the most important results of 
the TCCC and JTS was the renewed emphasis of tourniquet use to treat major arterial bleed 
extremity injuries.(61) 
Though extremity injuries fell to 39 % in Iraq and Afghanistan,(30) severe limb trauma 
accounted for up to 20 % of combat injuries.(60) As the rate of preventable deaths due to 
hemorrhage rose,(5, 28) TCCC guidelines adopted the use of tourniquets for prehospital 
control of extremity hemorrhage. In a study of patients at a combat hospital in Baghdad, 
Kragh et al. found that use of a tourniquet in the field increased survival by 13 %.(59) 
Survival rates skyrocketed to  80 % if the tourniquet was applied before the patient went into 
shock (Figure 11).(59) Over the 6 month period, Kragh found that tourniquet use saved 31 
lives.(59) Overall, tourniquets have prevented mortality in as many as 2,000 US combat 
soldiers.(27) 
Furthering the benefits of tourniquet use, Swan et al. tested conventional wisdom limiting 
tourniquet use if the injury is below the elbow or knee, if the patient reports pain as a result 
of tourniquet placement, or if manual pressure can be used to occlude the injured blood 
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vessel.(62) In all three conditions, conventional wisdom was invalid with a conclusion to use 
a tourniquet whenever possible to stop bleeding.(62) Along with the proliferation of 
hemostatic devices and tranexamic acid in trauma management (detailed below), tourniquet 
use was credited with preventing greater mortality after the Boston Marathon bombings.(27) 
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Figure 11. Prehospital tourniquet use in extremity injuries increased survival by 13 %. 
This rate increased to 80 % if the tourniquet was applied before the patient went into 
shock. Survival increased 92 % if a tourniquet was used at all. Reprinted from Annals 
of Surgery, Vol. 249, Issue 1, JF Kragh, TJ Walters, DG Baer, CJ Fox, CE Wade, J 
Salinas, JB Holcomb, Survival with emergency tourniquet use to stop bleeding in major 
limb trauma, 1-7, Copyright (2009), with permission from Wolters Kluwer Health, 
Inc.(59) 
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E. Topical Devices 
For critical accessible injuries where tourniquets were ineffective, hemostatic application 
(delivery) agents such as impregnated gauzes were developed and rushed into service. In 
2006, Pusateri, Alam, et al. postulated seven characteristics for an ideal hemostatic dressing. 
The ideal hemostatic dressing should (1) stop all arterial and venous bleeding within 2 
minutes of application on the wound; (2) be ready to use immediately; (3) be simple to apply 
to the wound; (4) be lightweight and durable; (5) be stable and function at room temperature 
for at least 2 years and for several weeks at temperatures between -10oC and 55oC; (6) cause 
no adverse effects; (7) be inexpensive.(63) 
Though many hemostatic agents were proposed and extensively tested, silica-based 
materials proved exceptional at improving clotting function for arterial bleeding. Silica-based 
materials clot quickly, are stable for years, are easily applied to wounds, and are inexpensive 
to produce, fulfilling Pusateri’s characteristics of an ideal agent. While many variations of 
silica have been tested in preclinical and clinical trials, kaolin, the active ingredient in 
QuikClot Combat Gauze (Z-Medica, Wallingford, CT), was identified as a potential agent at 
UCSB,(64) found to meet all of the requirements put forth by Pusateri, Alam et al,(63, 65-69) 
and rushed to the battlefield.(70) As a result of this work, Professor Stucky was honored with 
the Department of Defense's Advanced Technology Applications for Combat Casualty Care 
Award in 2008. Kaolin-impregnated Combat Gauze remains the current device still 
recommended for all U.S. uniform service branches after seven years of field use under 
TCCC.(70) The identification and development of silica-based agents as clotting agents will 
be further explored in the second chapter. 
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Chitosan is a linear polysaccharide shellfish byproduct composed of (1–4)-linked 2-
amino-2-deoxy-D-glucose (D-glucosamine) and 2-acetamide-2-deoxy-D-glucose (Nacetyl-
D-glucosamine).(71) Sold commercially as the product Celox, chitosan is the preferred 
external wound agent used by the UK military medical command.(72) Upon contact with 
blood at the injury site, chitosan attaches to the damaged tissue and swells up to form a gel 
that seals the wound and prevents further blood loss.(73) Unlike dehydrated zeolite in the 
first generation of QuikClot,(63) chitosan does not release heat upon contact with blood.(73) 
Chitosan also acts outside of the coagulation milieu as it holds a positive surface-charge and 
acts by binding to anionic sites on red blood cells to initiate clotting.(71)  
In addition to promoting clotting in open wounds, chitosan is also biocompatible and 
antimicrobial.(74) While no adverse effects have been reported with regard to shellfish 
allergies,  the sole study on the safety of chitosan use in patients with shellfish allergies was 
conducted with only 10 participants.(75) 
In conjunction with improved treatment protocols, the proliferation of silica-based 
hemostatic agents led to the reduction of case fatality rate in Iraq from nearly 20 %(76) at its 
peak in 2003 to 10.9 % during the troop surge in 2007-2008.(77) Adoption of TCCC 
guidelines, including kaolin silica hemostatic agents, by civilian trauma sectors were 
instrumental in preventing the loss of further life and limbs during the Boston Marathon 
Bombings.(27) 
F. Recombinant Proteins 
Recently, hemostatic compounds, such as recombinant human proteins, have been 
developed that are endogenous to the body. The most notable is recombinant factor VIIa 
(rFVIIa), the FDA’s first approved recombinant protein treatment to be used in general 
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trauma patients despite its indication only for hemophilia patients. RFVIIa promotes 
hemostasis through its activation of the extrinsic coagulation pathway. RFVIIa binds to tissue 
factor, which is exposed at the injury site. As a secondary mechanism, rFVIIa also binds to 
platelets, increases thrombin burst, and increases clot strength.(38)  
While recombinant proteins can be very effective, they also have serious limitations. 
Agents are designed for a specific subset of patients – e.g., rFVIIa for hemophiliacs. In 
general trauma patients, there are no FDA guidelines for dosage or administration and these 
drugs are often used as a last resort measure to save the patient.(78) In addition, recombinant 
proteins are extremely expensive. As such, drugs like rFVIIa are viewed as a panacea for 
late-stage bleeding when the reality is that these drugs are ineffective at this point of the 
trauma trajectory and could be far more effective if utilized before the patient’s coagulation 
capabilities became irreparably impaired.(78) However, the excessive cost and safety 
questions in using these biological agents are major concerns that often limit use until late 
stage blood loss in trauma patients.(79)  
Despite anecdotal successes, multiple studies showed that the use of rFVIIa does not 
significantly improve outcomes in bleeding patients and may result in thrombotic 
complications.(78, 80) O’Connell et al. found that use of rFVIIa in non-hemophiliac bleeding 
patients led to increased risk of thromboembolic event, particularly within rFVIIa’s 2 hour 
half-life after rFVIIa administration cease.(41) In the larger CONTROL trial, rFVIIa was 
found to have no increase in thromboembolic risk compared to any other procoagulant 
treatment. More damning though, the CONTROL trial found that rFVIIa reduced blood 
product use but did not reduce mortality.(81) As a result, rFVIIa has fallen out of favor in the 
trauma community. Other agents, including prothrombin complex concentrates and 
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antifibrinolytics, are currently being evaluated but act within the coagulation milieu and are 
unlikely to provide improved coagulation and hemostasis in the setting of the severely 
impaired coagulation that is ATC. 
In a study of 450,375 trauma patients, 1602 (0.36%) developed a venous 
thromboembolism after injury.(39, 40) Within the subset, roughly 600 suffered from a life-
threatening pulmonary embolism. 18.7 % of patients with a pulmonary embolism died.(39) 
Risk factors for embolism include age, the type of injury suffered, presence of shock, and the 
need for major surgery.(39) 
As with rFVIIa, prothrombin complex concentrates (PCCs) were developed for a specific 
subsection of hemorrhage patients.(82) PCC is composed of multiple proteins – prothrombin 
(FII), FVII, FIX, FX, and protein C – and is designed to quickly reverse the effect of the 
anticoagulant warfarin in patients who are hemorrhaging or require surgery.(83) As with 
rFVIIa, PCC is used off-label to treat trauma patients. Fries et al. found that in a dilutional 
coagulopathic model with a liver injury in swine, combining PCC with fibrinogen led to 100 
% survival rate compared to less than 20 % with placebo.(84) In a similar swine liver injury 
model, Honickel et al. found that PCC and fibrinogen were also effective in minimizing 
blood loss and increasing survival rates under severely hypothermic conditions.(85)  
PCC is now given with fibrinogen concentrate(86) to supplement the use of FFP. PCC 
and fibrinogen may improve coagulation profiles due to its ability to supplement the 
coagulopathic system with five unactivated factors as opposed to the single factor 
rFVIIa.(87) This increases the likelihood that coagulopathy cannot impair all five factor 
mechanisms. Aside from cost, the greatest concern with combined PCC and fibrinogen usage 
is the potential for thromboembolic events. In a study conducted at the University of Arizona, 
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7 % (3 of 45) of trauma patients receiving PCC and fibrinogen suffered unwanted 
thrombosis.(88) However, this risk of embolism was consistent with rates seen in patients 
receiving FFP without PCC.(87) 
G. Tranexamic Acid 
Tranexamic acid (TXA) is a synthetic version of lysine used in patients at risk for 
bleeding complications.(89) TXA was among a group of antifibrinolytics originally 
developed to minimize blood loss in patients at risk for postoperative complications.(90) Due 
to its success in reducing need for blood transfusion by one-third,(90) TXA use grew to 
include patients suffering traumatic injuries. In a Clinical Randomisation of an 
Antifibrinolytic in Significant Haemorrhage (CRASH-2) study, TXA lowered hemorrhage 
mortality significantly when compared to saline placebo (p = 0.0077, Table 1) in over 20,000 
civilian patients.(8) As an antifibrinolytic, TXA is thought to reduce blood loss and overall 
mortality by binding to plasminogen, thereby inhibiting plasminogen’s ability to break down 
the physical fibrin clots.(8) However, further studies on TXA and other antifibrinolytics posit 
that the mechanism for lowering mortality may be caused by TXA’s ability to minimize the 
inflammatory effects of the protein plasmin.(91)  
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Table 1. Tranexamic acid lowered bleeding mortality without increasing non-bleeding 
mortality. Reprinted from The Lancet, 376/6736, the CRASH-2 collaborators, Effects of 
tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma 
patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled 
trial, 23-32, Copyright (2010), with permission from Elsevier.(8) 
 Tranexamic acid 
(n=10 060) 
Placebo 
(n=10 067) 
Relative Risk 
(95% CI) 
p value 
(two-sided) 
Any cause of death 1463 (14.5%) 1613 (16.0%) 0.91 (0.85–0.97) 0.0035 
Bleeding 489 (4.9%) 574 (5.7%) 0.85 (0.76–0.96) 0.0077 
Vascular occlusion 33 (0.3%) 48 (0.5%) 0.69 (0.44–1.07) 0.096 
Multiorgan failure 209 (2.1%) 233 (2.3%) 0.90 (0.75–1.08) 0.25 
Head injury 603 (6.0%) 621 (6.2%) 0.97 (0.87–1.08) 0.6 
Other causes 129 (1.3%) 137 (1.4%) 0.94 (0.74–1.20) 0.63 
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Furthermore, the benefit of TXA is strictly time-dependent: TXA administration 
immediately after injury led to a much greater survival rate in patients.(92) Conversely, the 
use of TXA more than 3 hours after injury decreases survival rate (Figure 12), potentially due 
to the increased likelihood of disseminated intravascular coagulation in later-stage trauma 
patients.(92) The use of tranexamic acid within 1 hour lowered hemorrhage-related mortality 
from 7.7 % to 5.3 % compared to placebo; treatment between 1 – 3 hours lowered mortality 
from 6.1 % to 4.8 %.(92)  
Based on the CRASH-2 study, the military adopted TXA as a key component of clinical 
hemorrhage care.(10) Army studies suggest that TXA remains stable in prehospital 
conditions for up to 12 weeks, though it is primarily used by surgeons in a hospital 
setting.(93) As in the CRASH-2 study, the Military Application of TXA in Traumatic 
Emergency and Resuscitative Surgery (MATTERs) found that TXA did lead to reduced 
mortality and need for massive transfusion for patients who survived for at least 24 hours. 
The greatest statistical data point for TXA was that it limited the need for massive 
transfusions in 1 out of 7 patients, whereas it produced a mortality benefit of only 1 in 67 
patients.(10) However, the MATTERs study found no statistical difference between TXA 
and non-TXA use in preventing mortality within 24 hours.(10) The use of TXA in more 
severely injured patients is one of the many reasons that may account for this discrepancy. 
More concerning was the fact that TXA use in combat situations led to unwanted thrombotic 
events. However, the study size was too small to assess the risk for unwanted thrombosis as a 
direct result of TXA use.(10)  While TXA is established as an excellent agent for reducing 
blood loss and restoring hemostasis, newer drugs are still needed to improve mortality in the 
24 hour period after injury when the patient is at greatest risk for exsanguination. 
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Figure 12. Survival odds ratio (OR) with a 95 % confidence interval (CI) for patients 
given TXA as opposed to placebo. OR is at 0.61 if TXA is given immediately upon 
injury and rises by a factor of 1.15 every hour until TXA. After 3 hours, patients given 
a placebo are more likely to survive. Reprinted from The Lancet, 377/9771, the 
CRASH-2 collaborators, The importance of early treatment with tranexamic acid in 
bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised 
controlled trial, 1096-1101, Copyright (2011), with permission from Elsevier.(92)  
 
 
 
  
  32 
 
H. Conclusion 
The development of coagulopathy in the trauma patient is a key warning that intervention 
is required for survival. There are a myriad of agents that can aid the impaired clotting 
system to help replenish the blood that has been shed and prevent further loss of blood. At 
this time, prothrombin complex concentrates and tranexamic acid are the two most utilized 
clotting agents in trauma surgeries to restore clotting capabilities in patients. However, these 
agents are not without limitations. The extreme cost, storage requirements, and risk for 
unwanted thrombotic events if used contrary to indications must be weighed by the clinician 
before using these agents. One potential treatment that can mitigate these questions is the 
inorganic compound silica. Whether on its own or used to deliver a procoagulant payload, 
silica is used in a new class of agent that is cheaper, stable at ambient conditions, and 
functionalized to prevent unwanted coagulation. It is the preferred agent for point of care 
topical application as a hemostasis agent to stop major arterial bleeding that is unexpectedly 
induced either by combat or civilian trauma situations.  
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II. Silica Hemostatic Agents 
The fate of the wounded lays with those who apply the first dressing. 
- Col. Nicholas Senn, US Army, 1844 - 1908 
A. Introduction  
Ratnoff first discovered Factor (F)XII, then known as the Hageman factor, in 1955 in 
diagnosing a patient who had prolonged clotting times for intrinsic pathway tests without 
abnormal clotting function during surgery.(94) By 1961, Margolis had discovered that FXII 
was activated by adsorption onto a silica nanoparticle surface, which initiated coagulation 
(Scheme 1). He further found that the clotting activity depended on the size of the silica 
particle, with peak clotting activity occurring at 30 nm.(95) While researchers used materials 
such as silica glass and kaolin for their clotting assays, they were not considered for 
hemostasis treatment.(96)   
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Scheme 1. Simplified coagulation cascade. In the presence of blood, silica induces the 
activation of FXII to initiate the intrinsic (contact activation) pathway. 
 
  
  35 
 
B. Use of naturally occurring silicates to control bleeding.  
Despite knowledge of its effect on FXII and the intrinsic pathway, the use of silica or 
silicates for hemorrhage treatment was not recognized until the 21st century. Out of many 
inorganic oxide compounds, a 3-D nanoporous aluminosilicate zeolite with a water 
accessible surface area of ~500 m2/g proved effective in lowering clot time while also 
accelerating clot growth (Figure 13).(13)  This dehydrated calcium substituted zeolite 
(Na0.5Ca5.75(SiO2)12(AlO2)12·xH2O), used commercially for nitrogen-oxygen separation from 
dry air, was serendipitously (97) found to be a good coagulating agent, and was initially 
applied in the same dehydrated powder particulate form as used for oxygen-nitrogen 
separation. This was the original aluminosilicate (QuikClot (QC)) that was used as a 
therapeutic for arterial bleeding in the field.  
In 2004, Alam et al. showed that application of this zeolite-impregnated gauze reduced 
mortality to 0 % in swine with a severe groin injury (Figure 14).(98) Pusateri et al. found that 
impregnating the silicate zeolite on gauze for treating wounds reduced blood loss, reduced 
the need for resuscitative fluids, hastened the animal’s return to hemostasis, and increased 
survival by 76 % on a lethal liver injury (Figures 14 and 15, Table 2).(63, 98) This marked a 
major improvement over what was then the state of the art for field use. However, there was 
intense heat released due to the exothermic adsorption of water onto the zeolite’s dehydrated, 
high surface area (~500 m2/gm) 3-D nanostructure. 
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Figure 13. In vitro clotting time (R) and rate of clot growth (α) of various inorganic 
oxides. Zeolite is one of the strongest procoagulant oxides with a low clot time and large 
clot growth. Reprinted (adapted) with permission from Langmuir, Vol. 23, Issue 22, TA 
Ostomel, Q Shi, PK Stoimenov, GD Stucky, Metal oxide surface charge mediated 
Hemostasis, 11233-11238 , Copyright (2007) American Chemical Society.(13) 
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Table 2. In vitro clotting parameters for various ion-exchanged zeolites. Swine survival 
rate shows that only unexchanged zeolite led to 100 % swine survival. Springer and the 
Journal of Thrombosis and Thrombolysis, Vol. 22, 2006, 55-67, Host-guest composites 
for induced hemostasis and therapeutic healing in traumatic injuries, TA Ostomel, PK 
Stoimenov, PA Holden, HB Alam, GD Stucky, Table 3, original copyright notice) is 
given to the publication in which the material was originally published, by adding; with 
kind permission from Springer Science and Business Media.(99) 
Agent R (min) α (o) MA (mm) Survival (%) 
Ag-Exchanged Zeolite 0.9 ± 0.7 52.0 ± 7.2 75.6 ± 8 75 (6/8) 
Ba-Exchanged Zeolite 1.8 ± 0.2 64.6 ± 1.2 76.9 ± 1.2 75 (6/8) 
Na-Exchanged Zeolite 2.1 ± 0.2 62.0 ± 0.6 73.3 ± 57 (4/7) 
K-Exchanged Zeolite 2.2 ± 0.6 59.6 ± 2.9 77.5 ± 0.9 0 (0/2) 
Sr-Exchanged Zeolite 2.1 ± 0.2 60.8 ± 1.9 73.7 ± 2.6 0 (0/2) 
Citrated sheep blood 10.9 ± 1.3 50.2 ± 11.3 77.4 ± 2.5 NA 
Zeolite 1.8 ± 0.1 67.8 ± 1.3 79.6 ± 1.1 100 
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Figure 14. Survival rate over time for a complex swine groin injury for various 
treatments. ND, no dressing; SD, standard dressing alone; 1% ZH, SD + 3.5 oz of 
zeolite hemostat with 1% residual moisture; 4% ZH, SD + 3.5 oz of zeolite hemostat 
with 4% residual moisture; 1% ZH 2oz, SD + 2 oz of zeolite hemostat with 1% residual 
moisture; 8% ZH, SD + 3.5 oz of zeolite hemostat with 8% residual moisture; HC, SD + 
HemCon hemostatic dressing; NZH, SD + 3.5 oz of nonzeolite hemostat; FA, SD + Fast 
Act bovine hemostatic dressing; TDex, SD +30 g of TDex hemostatic powder. Reprinted 
from The Journal of Trauma and Acute Care Surgery, Vol. 56, Issue 5, HB Alam, Z 
Chen, A Jaskille, RILC Querol, E Koustova, R Inocencio, R Conran, A Seufert, N 
Ariaban, K Toruno, P Rhee, Application of a zeolite hemostatic agent achieves 100% 
survival in a lethal model of complex groin injury in swine, 974-983, Copyright (2004), 
with permission from Wolters Kluwer Health, Inc.(98) 
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Figure 15. QC Zeolite achieves hemostasis after liver injury in swine faster than 
standard gauze. Reprinted from The Journal of Trauma and Acute Care Surgery, Vol. 
57, Issue 3, HB AE Pusateri, AV Delgado, EJ Dick, Jr., RS Martinez, JB Holcomb, KL 
Ryan, Application of a Granular Mineral-Based Hemostatic Agent (QuikClot) to 
Reduce Blood Loss After Grade V Liver Injury in Swine, 555-562, Copyright (2004), 
with permission from Wolters Kluwer Health, Inc.(63) 
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Eventually the use of this dehydrated zeolite was abandoned due to the huge release of 
heat upon contact with aqueous media, including blood, that led to serious burns when 
applied (Table 2, Figure 4).(63, 64) Pusateri et al. found that application of QC zeolite raised 
the temperature at the wound site to 93oC (Table 2).  Adding 10g of QC zeolite to 10 ml of 
stirred blood resulted in a 140.4 °C peak temperature (Figure 16).(63, 64) Titration of the 
zeolite with small amounts of water before packaging to eliminate the extreme heat generated 
by the dry zeolite gave a large improvement, over untreated wound hemostasis, in reducing 
the time necessary to initiate arterial clotting, increase the rate of clot formation and enhance 
the strength of the resulting clot.(99) Unfortunately, the in vivo and in-the-field effectiveness 
of this slightly hydrated zeolite to produce a high survivability for external major arterial 
bleeding was not adequate.(99) 
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Figure 16. Thermal images show that QuikClot zeolite releases significant heat upon 
addition to water. Kaolin does not. Reprinted from Chemistry of Materials, Vol. 19, 
Issue 18, SE Baker, AM Sawvel, N Zheng, GD Stucky, Controlling bioprocesses with 
inorganic surfaces: Layered clay hemostatic agents., 4390-4392, Copyright (2007) 
American Chemical Society.(64) 
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Table 3. Post-injury effects of standard gauze and QC zeolite on lethal liver injury in 
swine. Reprinted from The Journal of Trauma and Acute Care Surgery, Vol. 57, Issue 
3, HB AE Pusateri, AV Delgado, EJ Dick, Jr., RS Martinez, JB Holcomb, KL Ryan, 
Application of a Granular Mineral-Based Hemostatic Agent (QuikClot) to Reduce 
Blood Loss After Grade V Liver Injury in Swine, 555-562, Copyright (2004), with 
permission from Wolters Kluwer Health, Inc.(63) 
 
 
  
Variable Standard Gauze QC Zeolite p Value of Difference
Post-treatment blood loss (ml) 5338 +/- 806 1397 +/- 806 <0.01
Resuscitation fluid used (ml) 9686 +/- 1260 5574 +/- 1260 0.04
Peak temperature at tissue interface (
o
C) 37.5 +/- 0.01 93.3 +/- 10.5 <0.01
Survival to 1h 1/8 (12%) 7/8 (88%) <0.01
Survival time (min) 44.5 +/- 3.6 58.3 +/- 1.8 <0.01
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Research then shifted to focusing on what properties of the zeolite system made the 
dehydrated zeolite so effective as an arterial hemostasis agent when the zeolite system was 
interfaced with the blood clotting cascade system.(63, 64, 99) Calcium delivery to the blood 
system from the high surface area calcium zeolite (Na0.5Ca5.75(SiO2)12(AlO2)12·xH2O), local 
dehydration of the blood at the point of injury, the increase of temperature at the wound site, 
and the inorganic surface-blood factor interface interactions and chemistry were considered 
as possible clotting agent control variables for enhanced clotting efficiency.(99)  
While modestly higher temperatures (> 37 ˚C) and the release of calcium give positive 
responses for more efficient clotting, the most important variable identified from studies of a 
variety of possible inorganic agents was the inorganic particle surface charge as determined 
by measurements of the zeta potential in simulated body fluid (Figure 17).(64) In fact, it was 
found that the appropriate choice of zeta potential, which varies over a wide range for 
inorganic agents, could be used to selectively initiate and amplify both clotting and its 
antithesis, anticlotting in plasma and whole blood. With this as a guide, the most effective 
candidate was determined to be the non-swellable silicate clay kaolin, which does not 
exfoliate blood transportable low molecular weight aluminosilicate species,(66) has no 
exothermic reaction with water or blood, but as a hemostasis agent is as effective as calcium 
dehydrated zeolite.(14)   
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Figure 17. Decreasing surface zeta potential leads to decreasing clot time in silicate 
clays. Reprinted from Chemistry of Materials, Vol. 19, Issue 18, SE Baker, AM Sawvel, 
N Zheng, GD Stucky, Controlling bioprocesses with inorganic surfaces: Layered clay 
hemostatic agents., 4390-4392, Copyright (2007) American Chemical Society.(64) 
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Several other hydrated clay groups were tested. In addition to activating FXII, 
aluminosilicate smectite clays such as montmorillonite swell upon contact with blood, 
restricting blood flow while initiating coagulation at the point of injury. Studies conducted 
with porcine blood showed that Na-montmorillonite reduced clotting time by nearly one-
third (Figure 18).(14) Further refinement led to the development of the powder WoundStat 
(WS), a topical agent that combined smectite clay with a superabsorbent polymer to 
minimize blood loss. 
However, smectite clays also had the most serious side effects. In vivo studies with 
members of the swellable aluminosilicate layered clay family show significant in vivo 
cytotoxicity, probably due to their propensity for exfoliation.(100-102) As a result, WS was 
quickly removed shortly after FDA approval due to safety concerns over its cytotoxicity 
(Figure 19), the long-term effect of WS on treated vessels, and the occlusion of WS treated 
vessels by thrombin.(100, 102, 103) 
  
  46 
 
 
Figure 18. Clotting times of various silicates in porcine blood. Zeolites are in red. Non-
silicate hydrotalcite is in blue. Smectites are in green. Kaolin in magenta. Reprinted 
from Chemistry of Materials, Vol. 19, Issue 18, SE Baker, AM Sawvel, N Zheng, GD 
Stucky, Controlling bioprocesses with inorganic surfaces: Layered clay hemostatic 
agents., 4390-4392, Copyright (2007) American Chemical Society.(64)  
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Figure 19. (A) Untreated HUVEC cells and (B) HUVEC cells after treatment with 
WoundStat. Untreated HUVEC cells are healthy, while those treated with WoundStat 
show early stages of cell death. Reprinted from The Journal of Trauma and Acute Care 
Surgery, Vol. 71, Issue 3, PD Bowman, X Wang, MA Meledeo, MA Dubick, BS 
Kheirabadi, Toxicity of Aluminum Silicates Used in Hemostatic Dressings Toward 
Human Umbilical Veins Endothelial Cells, HeLa Cells, and RAW267.4 Mouse 
Macrophages, 727-732, Copyright (2011), with permission from Wolters Kluwer 
Health, Inc.(100) 
 
  
  48 
 
Of all naturally-occurring clays, independent extensive porcine in vivo blood clotting 
investigations by both Navy and Army medical research laboratories showed that kaolin 
(Al2Si2O5(OH)4 · 2 H2O) was highly effective as a blood clotting agent for major arterial 
bleeding from open wounds, yet, unlike zeolite, kaolin does not release heat upon contact 
with blood .(64) Extensive studies on the in vivo biocompatibility of kaolin were also 
made.(64) 
The use of kaolin in clotting assays dates back to the 1950s, but surprisingly was not 
considered as a hemostasis agent.(96) In the more recent studies referenced above with 
porcine blood, kaolin was found to induce clots with nearly the same strength (Figure 18) as 
dehydrated zeolite without the significant exothermic release (Figure 16).(64) By 2011, the 
percentage of combat casualties who died of their wounds fell below 5 % thanks significantly 
to the proliferation of topical hemostatic agents such as kaolin-based Combat Gauze.(29) 
The important conclusion from the studies is that there is tremendous variability in the 
efficacy and safety of different silica and silicate systems. Studies on the use and application 
of silica to activate the intrinsic pathway have taken advantage of naturally occurring 
silicates such as zeolites(98), smectites(64), and kaolin.(64), which are plentiful, produced 
cheaply, and have long shelf lives so that they are cost-effective in ton quantities. However 
these nanostructure materials are in fact themselves complex systems that can affect and 
direct the body and blood clotting systems in  markedly different ways, with the most 
effective, from a biocompatibility and hemostasis view, being pure nanostructured silica 
(nanoparticles or mesostructured) and kaolin.(104)  
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Table 4. Kaolin-based Combat Gauze greatly improves outcomes in treating groin 
arterial hemorrhage in swine. Reprinted from The Journal of Trauma and Acute Care 
Surgery, Vol. 67, Issue 3, BS Kheirabadi, MR Scherer, JS Estep MA Dubick, JB 
Holcomb, Determination of Efficacy of New Hemostatic Dressings in a Model of 
Extremity Arterial Hemorrhage in Swine, 450-460, Copyright (2009), with permission 
from Wolters Kluwer Health, Inc.(105) 
Outcome HemCon Celox-D 
Trauma-
Stat Placebo 
Combat 
Gauze 
Initial Hemostasis 
achieved 
(# applications) 0/6 (12) 0/6 (12) 1/10 (20) 1/6 (12) 3/10 (17) 
Total time 
bleeding stopped 
(min) 3.0 ± 2.2 0.5 ± 0.04 35.7 ± 22.2 57.9 ± 36.2 134.6 ± 22.2 
Pretreatment 
blood loss (ml/kg) 19.2 ± 1 21.8 ± 1.8 19.3 ± 1.2 19.3 ± 1.6 18.2 ± 0.7 
Posttreatment 
blood loss (ml/kg) 108.2 ± 7.5 113.8 ± 8.2 79.8 ± 13.8 75.5 ± 23.8 37.4 ± 17.3 
Total resuscitation 
fluid (ml/kg) 175.3 ± 24.8 189.1 ± 16.2 160.3 ± 14.4 186.2 ± 41.9 123.9 ± 27.2 
Survival rate 0/6 0/6 2/10 0/6 8/10 
Survival time (min) 74.3 ± 10.5 74.2 ± 5.8 90.0 ± 15.3 121 +/- 19.3 167.3 ± 5.9 
Peak wound 
temperature (°C) 36.8 ± 0.2 36.6 ± 0.2 36.6 ± 0.3 37.0 ± 0.1 35.7 ± 0.3 
 
  
  
  50 
 
Despite improvements in clotting function, concern remains over the toxicity of 
aluminosilicates in the human body.(106) In addition, human cell cytotoxicity studies of 
kaolin as well as swellable clays show substantial HUVEC cell degradation for all 
clays,(107) but not for mesoporous silica.(104)  The cytotoxicity of aluminosilicates for 
HUVEC cells, which are also used as models for studying blood-brain barrier processes, 
suggests that they should not be used for direct applications to open head injury wounds.  
Concern remains that a buildup of aluminosilicate species throughout the body might impair 
brain and kidney function. Pure silica species, however are much less HUVEC cell cytotoxic, 
and mesoporous silica with 10 kDa polyethylenimine improves cell viability without 
negative side effects.(108) Recent in vitro studies also suggest that magnesium ions in 
laponite (Na0.7Si8Mg5.5Li0.3O20(OH)4) improve cell growth.(109, 110) 
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Table 5. Kaolin greatly increases outcome compared to unimpregnated gauze. 
Reprinted from Journal of Surgical Research, Vol. 183, Issue 2, MJ Sena, G Douglas, T 
Gerlach, JK Grayson, KO Pichakron, D Zierold, A pilot study of the use of kaolin-
impregnated gauze (Combat Gauze) for packing high-grade hepatic injuries in a 
hypothermic coagulopathic swine model, 704-709, Copyright (2013), with permission 
from Elsevier.(65) 
 
 
 
 
  
Value Kaolin Gauze Plain Gauze P value 
Injury area (cm2) 37 (6) 36 (8) 0.46 
Fluid administered (ml/kg) 7 (29) 44 (45) 0.06 
Blood loss (ml/kg) 25 (26) 58 (56) 0.05 
Survival after 2 h (yes: no) 7:1 4:4 0.11 
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C. Inorganics to treat non-compressible, blunt trauma wounds  
In Iraq and Afghanistan, wounds due to blunt and non-penetrating objects greatly 
increased the number of injuries in the head, neck, and trunk.(30) These injuries are non-
compressible, which limits the effectiveness of tourniquets and topical agents. There is 
presently little that can be done to stem internal bleeding prior to arrival at a surgical care 
center. The main concern in all instances of non-compressible hemorrhage is that patients 
exhibiting severe blood loss will become coagulopathic and die before surgery can restrict 
blood loss.(9) Acute traumatic coagulopathy (ATC) can develop as a result of tissue injury 
and hemorrhagic shock and is further complicated by other multifactorial, systemic 
factors.(34) 
Improving on the ideal topical hemostatic agent, the ideal agent to control non-
compressible hemorrhage in the prehospital setting would have the following properties: [1] 
long shelf-life and stability in weather extremes, [2] reasonable cost, [3] capability to 
promote key functions of the blood clotting system at the injury site including coagulation, 
regulatory anti-coagulation and fibrin formation, [4] lack of off-target adverse effects. Such 
an agent must at the same time enable treatment during the transport phase when the patient 
is at the greatest risk for exsanguination.  
D. Use of functionalized silica as a drug delivery agent 
Pure silica is generally considered to be a non-toxic material, and often used in drug 
delivery studies.(111-117) Due to its negative surface charge, silica is also a potent contact 
activator in the bloodstream.(64, 95) , which can be mediated with covalently attached 
surface capping agents such as polyethylene glycol (PEG).(114) The particle’s intrinsic 
negative surface charge at body pH allows FXII to bind to the silica surface and become 
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activated so that it is inherently a procoagulant.(95) Mesoporous nanoparticles can be gated 
to release therapeutic agents at targeted sites, which has been well demonstrated for cancer 
treatment.(113) Unlike pure silica, current materials used for treating external hemorrhage 
generally contain particles in the micrometer range, which are too large to easily traverse 
capillaries and unsuitable for use as intravenous therapeutics.(118) Consequently, the ideal 
construction of an intravenous hemostat with a silica nanoparticle (SNP) core would shield 
the SNP surface from exposure to the systemic circulation, while targeting exposure of the 
SNP carrier surface and the attached drug at the site of injury. Cytotoxicity tests are one of 
the main challenge thresholds needed to validate that the use of the SNPs intravenously is 
safe.  
Porous SNPs and p-doped silicon nanoparticles with a thin coating of silica are attractive 
for use in drug delivery and imaging due to key tunable and readily accessible properties 
such as small size, pore volume, large surface area, uniformity in synthesis, and 
processability.(115) Sailor et al. has shown that silicon nanoparticles can be used to image 
tumors and internal organs in mice without significant side effects (Figure 20).(119) Most 
important to drug delivery schematics, mesoporous silica can be loaded with proteins or 
drugs for targeting and delivery to systems and trauma sites in the body.(104, 120) For 
example, Slowing et al. have successfully synthesized mesoporous silica nanoparticles 
(MSNs) with an average diameter of 100 nm, 900 m2/g surface area, 2 nm pore size, and 0.9 
cm3/g pore volume (Figure 21).(115) Silica has also been proven to be biodegradable at a pH 
of 7.4, though the degradation process takes several hours or longer depending on the silica 
wall or particle thickness.(121) Lu et al. found that injecting mice with 50 mg/kg MSNs 
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showed no effects of toxicity over a two month study. Furthermore, the silica that did not 
degrade in the body was removed from the body through liver and kidney excretion.(122)  
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Figure 20. (a) Sailor’s silicon nanoparticles were viable in in vitro HeLa cell assays. (b) 
In vivo biodistribution of silicon nanoparticles after 4 weeks in a mouse. (c) The mouse 
weight did not change whether the mouse was injected with particles or PBS buffer. (d) 
Liver, spleen, and kidney histology at various time points. Reprinted by permission 
from Macmillan Publishers Ltd: Nature Materials, Vol. 8, Issue 4, J-H Park, L Gu, G 
von Maltzahn, E Ruoslahti, SN Bhatia, MJ Sailor, Biodegradable luminescent porous 
silicon nanoparticles for : in vivo: applications, copyright (2009).(119) 
  
  56 
 
 
Figure 21. Confocal fluorescence images of fluorescein labeled MSN (green, panel a; 
red, panel b) endocytosed by HeLa cells (blue) show that MSNs with high surface 
charge escape cellular uptake; d) shows panels a), b), and c) merged together. 
Reprinted from Advanced Drug Delivery Reviews, Vol. 60, Issue 11, II Slowing, JL 
Vivero-Escoto, C-W Wu, S-Y Lin, Mesoporous silica nanoparticles as controlled release 
drug delivery and gene transfection carriers, 1278–1288, Copyright (2008), with 
permission from Elsevier.(115)  
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Other strategies have sought to use porous silica to deliver key procoagulant proteins 
such as thrombin. Mesoporous SNPs are easily loaded  with procoagulant materials such as 
thrombin to selectively promote coagulation.(14) Mesocellular foam silica (MCF) was 
synthesized with pore sizes varying from 6-33 nm in size (Figure 22). TEG studies showed 
that MCF with pore sizes at 20 nm (MCF-20), 26 nm (MCF-26), and 33 nm (MCF-33) 
greatly reduced clotting time, while MCF-26 and MCF-33 also rapidly accelerated α or the 
rate of clot formation. 2 mg unadulterated MCF reduced clotting time nearly as effectively as 
packaged QuikClot. However, when bovine thrombin was immobilized in MCF-33, the clot 
time was reduced nearly in half when compared to commercial QuikClot, using smaller 
amounts of clotting agent. While exciting for topical wound dressings, the large MCF-33 
micron particle size and the strong clotting initiator nature of thrombin as a deliverable 
therapeutic prevents its use as an intravenous agent.(14) 
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Figure 22. Diagram of porous silica mesocellular foam (MCF). MCF-26 corresponds to 
a 26 nm window (pore) size. Reprinted with permission from Langmuir, Vol. 24, Issue 
24, SE Baker, AM Sawvel, J Fan, Q Shi, N Strandwitz, GD Stucky, Blood Clot 
Initiation by Mesocellular Foams: Dependence on Nanopore Size and Enzyme 
Immobilization, 14254–14260. Copyright 2008 American Chemical Society.(14)  
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In cytotoxicity studies, MCF-26 far outperformed clays such as kaolin, bentonite, and 
montmorillonite. MCF-26’s inability to adhere strongly to cell surfaces played an integral 
role in improved biocompatibility. The biocompatibility variability of a series of 
aluminosilicate and silica particles was greatest when tested on human umbilical vein 
endothelial cells (HUVEC). Kaolin, bentonite, and montmorillonite all had IC50 values well 
below 250 μg/ml on all three HUVEC cell lines. In comparison, the pure silica MCF-26 had 
an IC50 value above 1 mg/ml for all cell lines. Pure silica MCF-26 did damage HUVEC cells 
at a concentration of 7 mg/ml, nearly 30 times more concentrated than kaolin to produce the 
same effect. Even at 7 mg/ml, MCF-26’s did not kill 50 % of human epidermal keratinocytes 
(HEK) cells (Table 6).(104) In all samples tested, MCF-26 remained 10-30 times less 
cytotoxic than its clay counterparts.(104) The extremely low IC50 for kaolin and other clays 
suggests that their use should be avoided in brain injuries.   
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Table 6. IC50 values and cell viability for kaolin, montmorillonite, and MCF-26. 
Reprinted from Toxicology Research, Vol. 2, Y Li, AM Sawvel, Y-S Jun, S Nownes, M 
Ni, D Kudela, GD Stucky, D Zink, Cytotoxicity and potency of mesocellular foam-26 in 
comparison to layered clays used as hemostatic agents, 136-144, Copyright (2013), with 
permission from the Royal Society of Chemistry.(104) 
 Kaolin  Montmorillonit
e 
 MCF-26  
Cell type IC50 (μg/ml) Cell viability 
250 μg/ml 
(%) 
IC50 
(μg/ml) 
Cell viability 
1000 μg/ml 
(%) 
IC50 
(μg/ml) 
Cell viability 
1000 μg/ml 
(%) 
HUVEC 
1 
125 ± 
47 
39 ± 5 65 ± 3 18 ± 0 >1000 75 ± 2 
HUVEC 
2 
48 ± 4 35 ± 2 33 ± 2 25 ± 3 >1000 73 ± 12 
HUVEC 
3 
51 ± 2 21 ± 2 95 ± 13 33 ± 4 >1000 65 ± 3 
HDF 1 >250 138 ± 14 272 ± 99 29 ± 1 >1000 66 ± 13 
HDF 2 >250 119 ± 8 335 ± 32 38 ± 5 >1000 130 ± 4 
HDF 3 >250 107 ± 3 454 ± 120 57 ± 1 >1000 122 ± 3 
HEK 1 >250 58 ± 2 >1000 78 ± 6 >1000 100 ± 3 
HEK 2 >250 51 ± 12 >1000 62 ± 2 >1000 66 ± 8 
HEK 3 181 ± 
44 
46 ± 2 >1000 69 ± 2 >1000 102 ± 12 
NIH/3T3 >250 96 ± 5 461 ± 22 38 ± 2 >1000 93 ± 9 
HK-2 >250 62 ± 6 >1000 66 ± 2 >1000 71 ± 13 
HPTC >250 77 ± 9 280 ± 27 34 ± 2 >1000 89 ± 11 
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In combining silicate nanoplatelets with gelatin, Gaharwar et al. recently have sought to 
develop a biocompatible(123) laponite-based sealant that can be injected directly into non-
compressible injuries to halt bleeding (Figure 23). Addition of the gelatin-silicate gel to 
human whole blood reduced clotting time by 77 % compared to untreated blood (Figure 24). 
In a lethal liver injury in rats, both the laponite-gelatin gel and kaolin-based Combat Gauze 
led to 100 % survival rates (Figure 25). As an added benefit, 200 μl gel was injected to better 
simulate treatment of a non-compressible injury in which topical agents like Combat Gauze 
are not applicable. Long-term exposure of kaolin and other aluminosilicate topical agents can 
result in serious complications that threaten the patient’s life. In terms of biocompatibility, 
the injected gel degraded within 28 days, caused less inflammation at the injury site than 
Combat Gauze, and did not lead to any systemic issues or mortality in rats.(124) While the 
gel successfully decomposed without side effects, the gel matrix needs to be injected 
intravenously with an unknown injury in order to determine the laponite-gelatin gel’s true 
potential as an injectable, battlefield agent. 
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Figure 23. Gel prepared by combing silicate nanoplatelets and gelatin. Reprinted with 
permission from ACS Nano, Vol. 8, Issue 10, AK Gaharwar, RK Avery, A Assmann, A 
Paul, GH McKinley, A Khademhosseini, BD Olsen, Shear-Thinning Nanocomposite 
Hydrogels for the Treatment of Hemorrhage., 9833–9842. Copyright 2014 American 
Chemical Society.(124) 
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Figure 24. Gelatin-silicate gel was nearly as effective as thrombin and more effective 
than current commercial topical hemostatic agents in in vitro studies. Reprinted with 
permission from ACS Nano, Vol. 8, Issue 10, AK Gaharwar, RK Avery, A Assmann, A 
Paul, GH McKinley, A Khademhosseini, BD Olsen, Shear-Thinning Nanocomposite 
Hydrogels for the Treatment of Hemorrhage., 9833–9842. Copyright 2014 American 
Chemical Society.(124) 
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Figure 25. Gelatin-silicate gel (9NC75) injected into rats increased survival rates in a 
lethal liver injury model. Reprinted with permission from ACS Nano, Vol. 8, Issue 10, 
AK Gaharwar, RK Avery, A Assmann, A Paul, GH McKinley, A Khademhosseini, BD 
Olsen, Shear-Thinning Nanocomposite Hydrogels for the Treatment of Hemorrhage., 
9833–9842. Copyright 2014 American Chemical Society.(124) 
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E. Conclusion 
 Though knowledge of silica’s effect on coagulation through FXII and the intrinsic 
pathway dates back to the 1950s, the use of silica to stop bleeding was only adopted early in 
the 21st century. The increase of preventable deaths due to compressible, extremity bleeding 
in Iraq and Afghanistan led to the development of impregnated gauzes designed to stop 
bleeding within minutes, even when standard issue gauzes proved ineffective.  Researchers at 
UCSB in collaboration with emergency medical personnel from the Office of Naval Research 
(ONR) experimented with zeolites, smectites, and other silicates until kaolin emerged as the 
best topical treatment to prevent patients from bleeding to death prior to hospital arrival. 
Today, US military personnel still carry QuikClot Combat Gauze, a kaolin-impregnated 
gauze, as a first-response treatment; kaolin-based gauzes are also used in the civilian sector. 
Though concerns about side effects, particularly in application to head wounds, remain, 
kaolin remains the battlefield standard to stop major extremity bleeding. 
However, silica’s procoagulant effects are not only tied to its activation of FXII. Silica is 
a common drug delivery agent. Though much of the focus on silica has been with an eye 
toward cancer therapeutics, in the research described here we have explored how SNPs might 
be used as a synergistic agent to deliver procoagulant payloads to injury sites while at the 
same time inducing clotting through FXII activation. Silica also improves emergency 
treatment due to its long-term shelf-life stability at ambient conditions. Preventing the spread 
of thrombi to healthy vessels and the quick removal of SNPs from the body remain the two 
most difficult challenges in blood clotting drug delivery. Though there are currently no FDA 
approved silica-based treatments for non-compressible hemorrhage, recent publications on 
cancer therapeutics illustrate silica’s ability to combine with other agents to form a 
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synergistic therapeutic. The studies described in this dissertation show promise towards the 
development of an intravenous agent that will revolutionize treatment of life-threatening 
bleeding. 
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III. Accelerating coagulation through polyphosphate-laden silica 
nanoparticles1  
Hey man of science with your perfect rules of measure, 
Can you improve this place with the data that you gather? 
- Bad Religion, I Want To Conquer The World 
A. Introduction  
Previously, I have covered the issues medical personnel face in managing hemorrhage 
both on the battlefield and in civilian trauma centers. The current treatments available fall 
into three broad categories: mechanical devices that compress the wound,(125) topical 
hemostatic agents,(64, 126) and intravenous hemostatic agents.(8, 79, 127) Each treatment 
has its benefits and limitations(100, 104, 128, 129) depending on the locus and scope of the 
injury. Researchers and clinicians are still developing and refining treatments that fit the 
guidelines for the ideal hemostatic agent (Chapter II). In this chapter, I propose that targeted 
short-chain polyphosphate-laden silica nanoparticles (polyP-SNPs) have the potential to 
fulfill these requirements. 
Because it is a strong clotting accelerator (Scheme 2), intrinsically biocompatible,(18) 
and a poor initiator of endogenous coagulation enzyme production, short-chain polyP is a 
reasonable candidate for the management of hemorrhage.(18, 130) Delivery of a polyP 
payload on a nanoparticle carrier could potentially be optimized to target the site of injury 
while minimizing the impact on the systemic circulation. Effective targeting and control 
                                                 
1 Adapted, with permission from John Wiley and Sons, from Angewandte Chemie 
International Edition, Vol. 54, Issue 16, D Kudela, SA Smith, A May-Masnou, GB Braun, A 
Pallaoro, CK Nguyen, TT Chuong, S Nownes, R Allen, NR Parker, HH Rashidi, JH 
Morrissey, GD Stucky, Clotting Activity of Polyphosphate-Functionalized Silica 
Nanoparticles, 4018-22, Copyright (2015). 
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would in theory minimize the risk of thrombotic complications that limit procoagulant 
therapy. In addition to the potential for better biosystem safety, the production cost for polyP 
is low compared to that of recombinant proteins and other intravenous clotting agents. Upon 
attachment to inorganic oxides, polyP also has the potential for long-term stability under a 
variety of storage conditions. 
In response to an injury, human platelets secrete short-chain polyPs of approximately 60-
100 monomers. Platelet-secreted polyP has a variety of wound-healing therapeutic effects, 
including enhanced activation of factors XI and V, which ultimately leads to enhanced factor 
X activity, and limitation of the activity of tissue factor pathway inhibitor, which results in 
accelerated thrombin generation.(131) PolyP also creates a stronger clot structure and 
resistance to fibrinolysis.(20, 132)  PolyPs with a chain length of 50-100 mer have been 
shown to not be strong clot initiating agents, although longer chain polyP (e.g. 500 mer) is 
adept at initiating clotting by activating FXII.(18) In addition, because of a ~90 minute half-
life in plasma due to the normal presence of phosphatase enzymes in the blood,(133, 134) the 
procoagulant effects are further limited.(20, 131, 134) These properties and the endogenous 
metabolism of polyP offers excellent biocompatibility that is much better than currently 
available topical agents such as kaolin, which are not metabolized. 
While long-chain polyP is a potent activator of the contact pathway,(18) short-chain 
polyP released from platelets has relatively poor capacity to activate factor XII.(18, 130) I 
employed relatively short-chain polyP for these studies in order to maximize the 
enhancement of downstream coagulation enzymatic steps (common pathway), while 
minimizing contact pathway activation. 
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As noted above, platelets serve as a polyP delivery agent, secrete procoagulants and 
clotting factors that promote blood coagulation, and initiate the formation of a clot-dissolving 
enzyme that degrades blood clots during the healing process. In my studies following up on 
the extensive research originally carried out by the Morrissey group,(18, 20, 130, 131, 134) I 
use free polyP as a benchmark.  In the research reported here, delivery agent bifunctionality 
is introduced by using SNPs as a procoagulant carrier for the polyP. 
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Scheme 2. Coagulation cascade. Silica initiates clotting by activating FXII of the 
intrinsic pathway (blue). PolyP (red) accelerates clotting by increasing FVa and 
thrombin, the key factor in the coagulation cascade, production. Short-chain polyP 
(red) binds to thrombin and enhances the rates of activation of FV and FXI leading to 
an earlier thrombin burst. Rapid thrombin generation leads to increased conversion of 
fibrinogen to fibrin, which combines with activated platelets to form the physical clot. 
Finally, thrombin production also facilitates increased activity in the anticoagulation 
pathway, which limits the spread of coagulation to uninjured vessels.(135) 
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B. Materials  
Ethanol (200 proof), tetraethyl orthosilicate (TEOS), ammonia NH4OH (28 wt%), (3-
aminopropyl)triethoxysilane (APTES) were supplied by Sigma Aldrich. Polyphosphate was 
purified from P70 (BK Giulini GmbH, Germany). Deionized water was obtained using a 
Milli-Q water purification system (Millipore). Frozen citrated pooled normal plasma (PNP) 
and Factor XII-deficient plasma were purchased from George King Biomedical (Overland 
Park, KS) and handled according to package instructions. Phospholipid solutions in 
chloroform were purchased in Avanti Polar Lipids: L-α-phosphatidycholine (PC) and L-α-
phosphatidylserine (PS). Sodium chloride, potassium chloride, sodium phosphate, dibasic 
and potassium phosphate were also purchased from BK Guilini GmbH (Germany). 
Polyphosphate was obtained from the Morrissey lab by solubilizing the P70 in 250 mM 
LiCl/50 mM LiBO3, pH 10.5 at 100 °C for 10 min. The resulting crude material was then 
purified by isopropanol precipitation, with fractions characterized by Western blotting. 
C. Synthesis of silica nanoparticles and polyphosphate coated silica nanoparticles 
 Silica is generally considered to be a non-toxic material, and it is often used in drug 
delivery studies.(111, 112)  However, due to its negative surface charge, silica is also a 
contact activator.(64, 95) Consequently, the ideal construction of a polyP-bearing silica 
nanoparticle would shield the silica from exposure to the systemic circulation, with targeting 
and exposure of the silica carrier surface and polyP at the site of internal hemorrhage.  
Current materials used for treating external hemorrhage generally contain particles in the 
micrometer range, which are too large to easily traverse capillaries and unsuitable for use as 
intravenous therapeutics.(118) I consequently developed an approach for the synthesis of 50 - 
100 nm diameter particles (Figures 29 and 30, Table 7).(64, 118) 
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SNPs were synthesized following a modified Stöber method.(136)  In a typical synthesis, 
TEOS and ammonia were added consecutively, dropwise into 57 mL of ethanol (EtOH) 
while stirring at 300 rpm at room temperature. Stirring was continued for 24 h. Differing 
amounts of TEOS (0.5 – 5 mL) and ammonia (0.5 – 4 mL) were used to produce a library of 
selectively sized nanoparticles with different diameters. To produce the desired 55 nm SNP, 
5 mL TEOS were added dropwise to 57 mL EtOH followed by 3 mL NH4OH (28 wt%). pH 
and particle size were measured directly after synthesis, in ethanol. The materials were 
recovered by centrifugation (14 k, 30 min) and washed three times with ethanol to remove 
impurities. After redispersing in ethanol by sonication (bath sonicator, Model FS20 Fisher 
Scientific), the products were dried overnight at 60 ºC. The powder was homogenized then 
calcined at 550 ºC for 4 h.  
In order to attach the highly anionic polyP to an oxide, I followed the model of Lorenz et 
al. who used zirconia, which like silica has a negative surface potential, as the scaffold for 
applications in protein separation and purification.(137) This attachment strategy exploits the 
Lewis acid properties of an oxide surface to bind polyP, overcoming the electrostatic 
repulsion.(138) 
To prepare the polyP coated SNP (polyP-SNP) the synthesized silica nanoparticles were 
first dispersed by sonication in Milli-Q water and placed at 30 ºC. Polyphosphate was 
dissolved in a separate Milli-Q water solution and was added dropwise under vigorous 
stirring. The solution was stirred overnight. The functionalized materials were recovered by 
two rounds of centrifugation (14 k, 30 min), each time washed with water and redispersed by 
sonication. PolyP-SNP products were dried overnight at 60 ºC. Successful modification was 
determined using dynamic light scattering (DLS) and zeta potential. Using phosphate 
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buffered saline solution (PBS) as the solvent at pH 7.4, functionalizing the SNP with P70 
increased particle size roughly 15 nm. 
D. Characterization of the particles 
1. Zeta potential and particle size determination  
Particle sizes and zeta potentials were measured by laser diffractometry using a Zetasizer 
Nano ZS instrument (ZEN 3600, Malvern Instruments) at 20 ºC with an incident wavelength 
of 633 nm and 173 º backscattering angle. Zeta potentials were measured in water at different 
pH values and in PBS buffer (approximately 137 mM NaCl, 2.7 mM KCl, and 12 mM 
phosphate, pH 7.4). Particle size was measured just after synthesis (with ethanol as a solvent) 
and again after the calcination step, in ethanol at 1 mg/ml. Disposable cuvettes were cleaned 
with ethanol and water prior to sample loading. 
The change in surface charge suggested the presence of polyP in undigested polyP-SNP 
(Table 1, SI Figure. 2). At physiological pH in PBS, both SNPs and polyP display a negative 
surface charge. In deionized water, the SNP surface charge ranged from -15 to -25 mV 
(Figures 27 and 28, Table 7).(135) In simulated body fluid (SBF) at physiological pH, SNPs 
had a surface charge of -50 to -60 mV. PolyP is negatively charged at physiologic pH due to 
a pKa1 between pH 1-2 (for all internal phosphates) and pKa2 between pH 7.2 and 8.2 (for 
the two terminal phosphates).(139) Upon functionalization of polyP to the SNP surface, the 
zeta potential of the polyP-SNP decreased from -20 to -30 mV to roughly -40 to -50 mV in 
water, confirming the attachment of the polyP. In SBF, both particles exhibited a strongly 
negative charge below -45 mV. 
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Figure 26. Size of SNPs after synthesis in ethanol measured using DLS.(135) 
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Figure 27. Both SNPs and polyP-SNP have a Zeta potential of roughly -50 mV in PBS, 
pH 7.4.(135) 
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Figure 28. Zeta potential of polyP-SNP and SNP in deionized water.(135) 
  
 77 
 
Table 7. The zeta potential and surface charge of the particles change when dispersed in 
water or phosphate buffered saline solution, pH 7.4.(135) 
Compound, Medium Zeta Potential (µV) Size (nm) 
SNP, H2O -24.4 ± 0.3 55.97 ± 2.19 
SNP, PBS -52.5 ± 2.1 74.00 ± 6.24 
PolyP-SNP, H2O -44.3 ± 0.3 53.79 ± 1.75 
PolyP-SNP, PBS -52.0 ± 3.2 78.18 ± 2.86 
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2. Morphology and structure of the particles 
The size, morphology, and structure of representative samples were observed via 
transmission electron microscopy (TEM). TEM micrographs (Figures 29, 30) were obtained 
on a FEI Tecnai G2 Sphera electron microscope with an accelerating voltage of 200 kV. 
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Figure 29. TEM images of polyP-SNPs.(135) 
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Figure 30. TEM images of SNPs.(135) 
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3. Digestion of polyP-SNP particles into phosphate monomers for malachite green assay 
PolyP content on the particles was quantified by the Morrissey lab by hydrolyzing polyP 
to monophosphate. Calf intestinal alkaline phosphatase (CIAP, a potent exopolyphosphatase) 
was added to PolyP at 37 ºC, followed by phosphate analysis using malachite green 
microassay.  The polyphosphate is quantified in units of phosphate monomer (MW 102). 
Malachite green identified concentrations of 56, 26, and 23 nmol PO3/mg SNP. 
4. Quantification of the polyphosphate on the nanoparticles 
Further quantification used inductively coupled plasma atomic emission spectroscopy 
(ICP-AES). 170.35 mg polyP-SNP particles were digested in 1M hydrochloric acid at  
100 °C for several hours to break polyP into phosphate ions. The resulting solution was 
decanted to remove the phosphorous-rich supernatant from solid SNPs. ICP-AES tests on the 
supernatant concentration revealed 1.5624 ppm P. The ppm ratios were converted to nmol 
PO3/mg SNP and the resulting ratio was found to be 29.6 nmol PO3/mg SNP, which 
correlates to the 26 nmol PO3/mg SNP determined through malachite green assay. Digestion 
of other polyP-SNP samples in hydrofluoric acid also identified the presence of phosphorous 
in the silica nanoparticles (Table 2, 3). However, the samples digested in HF were too dilute 
to reliably report the phosphorous concentration quantitatively. 
To quantify the polyP loaded on the SNP surface, the digested phosphate solutions were 
measured using both a malachite green assay and inductively coupled plasma atomic 
emission spectroscopy (ICP-AES). ICP-AES determined the 26 nmol PO3 sample (malachite 
green) had 29.6 nmol PO3/mg SNP. Assuming each polyP chain has 70 PO3 monomers, 
these data suggest 100 – 200 polyP molecules are attached to each SNP. 
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Table 8. Concentration of P (20x dilution) in a 170.35 mg polyP-SNP sample digested in 
1 M HCl as measured by ICP-AES.(135) 
Element Wavelength (nm) Units Avg Std Dev RSD 
Phosphorous 177.495 ppm 1.574 0.0105 0.6675 
Phosphorous 178.284 ppm 1.563 0.0038 0.2463 
Phosphorous 178.766 ppm 1.56 0.0054 0.344 
Phosphorous 213.618 ppm 1.565 0.0123 0.7855 
Phosphorous 214.914 ppm 1.55 0.0066 0.4243 
Average    ppm 1.562     
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Table 9. Concentration of P (9x dilution) in a 79.10 mg polyP-SNP sample digested in 1 
M HCl as measured by ICP-AES.(135) 
Element Wavelength (nm) Units Avg Std Dev RSD 
Phosphorous 177.495 ppm 11.06 0.0105 0.6675 
Phosphorous 178.284 ppm 11.08 0.0038 0.2463 
Phosphorous 178.766 ppm 11.08 0.0054 0.344 
Phosphorous 213.618 ppm 11.06 0.0123 0.7855 
Phosphorous 214.914 ppm 11.04 0.0066 0.4243 
Average    ppm 11.06     
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5. 31P NMR (Nuclear Magnetic Resonance) 
The decanted phosphate sample was dried and resuspended in deuterium oxide. The 
resulting suspension was measured using an Agilent Technologies 400 MHz, 400-MR DD2 
Spectrometer. A 31P NMR spectra showed evidence of phosphate from the digested polyP-
SNP sample. 
31P NMR and surface charge change qualitatively demonstrated polyP attachment. 
PolyP-SNPs were digested in acid to break down polyP into phosphate monomers. 31P NMR 
tests on the digested sample detected the presence of phosphorous.  
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Figure 31. 31P NMR spectrum of digested polyP-SNPs shows evidence of 
phosphorous.(135) 
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6. Determination of the clotting activity 
The clotting activity was determined by two methods: standard coagulometry and 
thromboelastography (TEG) (Thromboelastograph model TEG® 5000, Haemonetics). TEG 
is an accepted point of care test used by clinicians.(140) These tests measure several 
parameters that are relevant to coagulation, including initial time for clot formation (R, min), 
rate of clot formation (α, deg), time until clot reaches 20 mm (K, min) and clot strength 
(maximum amplitude (MA), mm). For these tests, the particles were dispersed in HEPES 
buffered saline (HBS) containing phospholipid (PL) vesicles and sonicated. The 
phospholipids were a mixture of 80 % phosphatidycholine (PC) and 20 % phosphatidylserine 
(PS) prepared by sonication of chloroform stocks in HBS, following the protocol by 
Morrissey et al.  All subsequent dilutions were made by diluting the stock dispersion in this 
same solvent. HBS is 100 mM HEPES (Sigma-Aldrich), 20 mM HEPES/NaOH buffer (pH 
7.5), and 0.02 % (w/v) sodium azide (Sigma-Aldrich).(141) 
For the coagulometry tests, 50 μL of the particles were placed into a pre-warmed 
coagulometer cuvette followed by 50 μL of pooled normal plasma. After incubating for 33 
minutes at 37 ºC, the contact pathway was activated and the mixture equilibrated to the 
chosen temperature, then 50 μL of pre-warmed 25 mM CaCl2 was added into the cuvette. 
The results are the average values from duplicate runs. 
In the TEG experiments, first 340 μL of plasma and 10 μL of the clotting agent were 
added in the TEG cup and incubated at 37 ºC. After 3 minutes, 20 μL of 0.2 M CaCl2 were 
added to the cup and the test was started immediately. Concentration- and size-dependent 
analyses were performed. The results shown are the average value of, typically, 4 to 6 
replicates. 
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I also monitored the formation of thrombin by fluorescence plate assay, using a thrombin-
sensitive dye T-butyloxycarbonyl-b-benzyl-L-aspartyl-L-prolyl-L-arginine-4-methyl-
coumaryl-7-amide (Boc-Asp(OBzl)-Pro-Arg-MCA)Boc-Asp(OBzl)-Pro-Arg-MCA (Peptides 
International, Louisville, KY).  This assay is used to calculate the thrombin burst time, which 
is related to clot formation time. 
E. Discussion 
By not using tissue factor to initiate clotting, I focused my clotting assays on the intrinsic 
and contact activation pathways. Negatively charged particles, such as the aluminosilicate 
kaolin (QuikClot® Combat GauzeTM) used for external injuries, activate the contact 
pathway.(64, 125) Because it is a poor clot initiator, polyP attachment shields SNPs in the 
systemic circulation, which is beneficial for use to control hemorrhage intravenously. I 
measured the impact of both bare SNPs and polyP-SNPs on clot time using 
thromboelastography (TEG, Figures 7 - 10) on pooled normal plasma (PNP). Both particles 
decreased the time to initial clot formation (R) in a concentration-dependent manner, with 
polyP-SNP being more potent at concentrations below 0.5 mg/ml. The clot time reported in 
figures 2 and 4 refers to the time to initial clot formation, which is key in illustrating how 
polyP-SNP successfully accelerates clotting. The agent used did not affect the overall clot 
size formed, only the time required to reach peak clot size. However, polyP has previously 
been shown to improve overall clot formation, in part by limiting the effect of fibrinolysis in 
plasma containing tissue plasminogen activator.(20, 134) 
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Figure 32. Sample thromboelastography curve.(135) 
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Figure 33. PolyP-SNP cuts clot time (R value using TEG) roughly in half versus SNP 
below 0.3 mg/ml.(135) 
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Figure 34. The Angle value for thromboelastography measurements correlates to the 
rate of clot growth. At low concentrations, polyP-SNP induced clots grow faster than 
SNP induced clots.(135) 
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Figure 35. The agent used had minimal impact on the maximum size of the clot formed 
in plasma.(135) 
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Next, the Morrissey lab evaluated the procoagulant activity of polyP-SNPs formed with 
differing loads of polyP (Figure 36). PolyP-SNPs of varying polyP loading were synthesized 
and shipped for analysis using the Morrissey lab’s coagulometer. The ability to promote 
coagulation was measured by adding polyP-SNP or polyP in solution to PNP. Coagulation 
was evaluated by measuring time to clot formation on a fibrometer (Figure 29). In comparing 
polyP payload, polyP-SNPs were more potent at activating the contact pathway than polyP in 
solution. 
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Figure 36. PolyP loaded onto silica lowers clot time compared to bare polyP when 
measured by fibrometry.(135) 
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Figure 37. Upon addition of polyP-SNP to recalcified plasma, rapid thrombin 
generation is seen. The blue color indicates cleavage of the fluorescent dye by thrombin, 
signifying active coagulation.(135) 
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Figure 38. PolyP-SNPs are superior to bare SNPs in their ability to generate a rapid 
thrombin burst. This difference becomes even more pronounced at lower 
concentrations (0.05 mg/ml). Thrombin generation is measured using a thrombin-
sensitive fluorescent dye.(135) 
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Figure 39. PolyP-SNPs are able to generate a rapid thrombin burst even at low 
concentrations. Thrombin generation is measured using a thrombin-sensitive 
fluorescent dye.(135) 
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In order to further explore the relative activities of the new materials, I evaluated the 
ability of the materials to generate thrombin, the terminal enzyme of the coagulation cascade 
and the primary determinant of the rate of fibrin formation.(18) PolyP-SNP again 
substantially outperformed its bare counterpart (Figures 37-39). 
I next evaluated whether polyP-SNPs were able to enhance the generation of downstream 
coagulation enzymes (common pathway). I eliminated any potential impact on contact 
activation by utilizing factor XII-deficient plasma and initiating coagulation using a small 
amount of lipidated tissue factor (LTF, 63 pM). As expected, bare SNPs did not affect TEG 
clot time in this system (Figure 40). In contrast, polyP-SNP did shorten the time to physical 
clot formation, though it did not change the overall clot growth (Figures 40, 41). This 
indicates that the polyP is accessible for binding to the relevant downstream coagulation 
proteins. Additionally, this response could also be evaluated in the clinical setting by 
comparing tests such as prothrombin time (PT) and partial thromboplastin time (PTT). 
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Figure 40. Adding PolyP-SNP to LTF shortens clot time in FXII-deficient plasma 
compared to LTF only or LTF + SNP.(135) 
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Figure 41. The maximum clot size formed in FXII deficient plasma was nearly identical 
regardless of the agent used.(135) 
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One of the problems facing emergency medical personnel is that current intravenous 
treatments have a significantly short half-life at ambient temperature. Even pure polyP 
nanoparticles only remain stable for hours.(130) In comparison, attaching polyP to silica 
greatly enhanced the stability and procoagulant function of polyP from hours to weeks. After 
bench-top storage at room temperature in both powder and aqueous suspensions, polyP-SNP 
clotting times remained constant for at least 24 weeks (Figure 42). The strong negative 
surface charge of polyP-SNPs also minimized aggregation in aqueous suspensions over the 
same time period. Injectable drugs with long-term shelf-life can be used by emergency 
medical personnel prior to hospital arrival without concern that the particles will degrade 
without refrigeration. This suggests that the polyP-SNP system is a candidate to be the first 
prehospital intravenous injection designed to treat internal injuries by accelerating the 
clotting system at bleeding sites. 
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Figure 42. PolyP-SNP suspended in aqueous solution retains its procoagulant function 
after weeks of storage at ambient conditions.(135) 
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F. Conclusion  
In this study, I successfully attached polyP to the surface of small-diameter SNPs and 
demonstrated that these polyP-SNPs are more potent than bare SNPs at promoting 
coagulation, likely due to polyP’s ability to accelerate the common pathway for active 
clotting processes.  PolyP-SNPs, like polyP in solution, are able to enhance downstream 
coagulation reactions resulting in a shorter time to clot formation. Even after long-term 
storage at regular room temperature, the polyP-SNP system retained its procoagulant ability. 
The polyP-SNP construct is consequently promising as a prohemostatic agent. Further in 
vitro exploration of polyP-SNP’s ability to induce clotting in simulated trauma conditions are 
required prior to translation to in vivo preclinical trials. (142) 
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IV. Accelerating Clotting in the Presence of 
the Lethal Triad with Polyphosphate-Laden 
Silica Nanoparticles 
It's all right, man 
I'm only bleeding, man 
Stay hungry, stay free 
And do the best you can 
- The Gaslight Anthem, We're Getting A Divorce, You Keep The Diner 
A. Introduction  
Clinicians have revised their definition of coagulopathy. Once thought to be one part of 
the lethal triad (factor-depleted coagulopathy, hypothermia, and acidosis),(143) acute 
traumatic coagulopathy (ATC) alone is now accepted as the integral factor for severe clotting 
impairment (Chapter 1, Figure 5).(33) As such, the lethal triad is now de-emphasized as a 
group of symptoms that develop in the critically injured patient after, but are not directly tied, 
to the onset of ATC.(33) However, the lethal triad is still a strong predictor that the patient is 
suffering from ATC (Tables 1, 2).(143) Furthermore, the lethal triad still impacts the 
coagulation cascade negatively and must be attenuated if the patient is to return to 
homeostasis. 
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Table 10. Risk factors for developing coagulopathy. Reprinted from The Journal of 
Trauma and Acute Care Surgery, Vol. 42, Issue 5, N Cosgriff, EE Moore, A Sauaia, M 
Kenny-Moynihan, JM Burch, B Galloway, Predicting Life-threatening Coagulopathy in 
the Massively Transfused Trauma Patient: Hypothermia and Acidoses Revisited, 857-
862, Copyright (1997), with permission from Wolters Kluwer Health, Inc.(143) 
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Table 11. Probability a patient will develop coagulopathy based on injury profile, 
systolic blood pressure, blood pH, and body temperature. Reprinted from The Journal 
of Trauma and Acute Care Surgery, Vol. 42, Issue 5, N Cosgriff, EE Moore, A Sauaia, 
M Kenny-Moynihan, JM Burch, B Galloway, Predicting Life-threatening 
Coagulopathy in the Massively Transfused Trauma Patient: Hypothermia and Acidoses 
Revisited, 857-862, Copyright (1997), with permission from Wolters Kluwer Health, 
Inc.(143) 
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 Because ATC is a systematic condition, it can only be studied in vitro using shed blood 
from trauma patients. In the absence of a supply of shed blood, the best method for 
simulating trauma in vitro is through the lethal triad. In this vein, pooled normal plasma 
(PNP) was diluted with isotonic saline to deplete factor levels, chilled below normal body 
temperature (37° C) during assays to produce hypothermia, and acidified with lactic acid to 
achieve metabolic acidosis.(33)  
 While treatment is always designed to improve a patient’s outcome, the use of 
resuscitative fluids can actually worsen coagulopathy.(9) A study on bypass patients who 
suffered major bleeding either during or after surgery identified a risk factor when the 
amount of crystalloids exceeded that of whole blood in blood vessels, a 50 % diluted whole 
blood marker (Figure 43).(144) In patients who have developed ATC, this critical dilution by 
crystalloids and colloids of factors can be fatal.(9) 
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Figure 43. Study of activated clotting time (ACT) in patients showed that the use of 
crystalloids to maintain blood vessel integrity began to inhibit the patient’s ability to 
clot once half the whole blood volume was replaced with crystalloids. Reprinted from 
Blood Cells, Molecules, and Diseases, Vol. 43, Issue 3, BS Bull, KL Hay, PC Herrmann, 
Postoperative bypass bleeding: A bypass-associated dilutional (BAD) coagulopathy?, 
256-259, Copyright (2009), with permission from Elsevier.(144) 
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Of the triad, hypothermia has the smallest effect on clot impairment.(145) The decrease 
in temperature appears to inhibit the initiation of coagulation the most, delaying factor 
activation but not affecting overall factor levels (Figure 44).(146) This is also shown on the 
thromboelastograph, where clot initiation and rate of clot formation are delayed, but overall 
clot strength remains unperturbed.(145) 
Unlike hypothermia, acidosis’ effects are more severe and widespread.(145) Normal 
blood has a pH of 7.4, which drops as a result of trauma. As the pH drops, both the rate of 
thrombin production and the overall level of thrombin decreases as well (Figure 44).(147) 
While sodium bicarbonate can return the blood’s pH to a normal pH level, effects from 
acidosis continue to inhibit coagulation for roughly 24 hours (Figure 45).(148, 149) Acidosis’ 
greatest effect is on thrombin production,(146, 147, 150) which then significantly slows both 
the rates of clot formation and clot growth.(145)  
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Figure 44. Thrombin production in a splenic injury model under normal (control), 
hypothermic, acidotic, and combined hypothermic and acidotic conditions. Thrombin-
Antithrombin III (TAT) complex is a marker for production of thrombin. Reprinted 
from The Journal of Trauma and Acute Care Surgery, Vol. 58, Issue 5, W Martini, A 
Pusateri, J Uscilowicz, A Delgado, J Holcomb, Independent Contributions of 
Hypothermia and Acidosis to Coagulopathy in Swine., 1002-1010, Copyright (2005), 
with permission from Wolters Kluwer Health, Inc.(146) 
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Figure 45. Even after neutralization with sodium bicarbonate, acidosis still inhibits the 
rate of clot formation (acceleration) and the overall clot size. Reprinted from The 
Journal of Trauma and Acute Care Surgery, Vol. 67, Issue 1, W Martini, Coagulopathy 
by Hypothermia and Acidosis: Mechanisms of Thrombin Generation and Fibrinogen 
Availability., 202-208, Copyright (2009), with permission from Wolters Kluwer Health, 
Inc.(148) 
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While great advances have been made in the resuscitation of the injured patient, 
attenuating bleeding and correction of coagulopathy remain vexing clinical problems. 
Mortality remains high in ATC patients; the best available resuscitation and surgical 
practices often are unsucessful in adequately controlling bleeding. ATC and the lethal triad 
are currently countered by hemorrhage resuscitative methods, including transfusion of blood 
and blood products and the use of hemostatic agents. Indeed, there remains a need for 
adjunctive agents aimed at stopping bleeding in many patients. To date there has been some 
sucess in this area and a wide array of hemostatic dressing agents have been sucessfully 
deployed. For noncompressible hemorrhage however there is a dearth of available agents. 
In 2010, Kheirabadi et al. called for the need for “a new class of hemostatic agent that 
can function independently of host coagulation activity”.(67) Such an agent would be 
particularly beneficial to trauma patients who become coagulopathic at the point of injury, or 
who acquire coagulopathy after clinical treatment as a result of resuscitation therapy and 
excessive surgical bleeding. The use of an endogenous hemostat that induces clotting without 
occluding the injured vessel would alleviate safety issues. If successful, such a hemostat 
could help treat internal bleeding. Even better, replacing recombinant human proteins with 
inorganic agents that have longer shelf lifetimes, cost significantly less to produce, and 
therefore have lower treatment costs, is highly desirable. 
Human recombinant factor proteins suffer from ineffectiveness, side effects, and steep 
cost per dose.(79) Recombinant factors also require refrigeration, which preclude their use in 
certain prehospital and austere far forward military environments delaying essential 
lifesaving care. The delay from time of injury to administration allows the patient to develop 
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coagulopathy as a result of significant blood loss. Tranexamic acid has a strict window of 
viability after injury and a disputed mechanism.(92)  
Among its many benefits, the mechanism of thrombin generation and long term stability 
of polyP-SNP at ambient conditions has the potential to ameliorate treatment at any point 
where the patient is at risk for exsanguination. I have previously shown that attaching polyP 
to SNPs to create polyP-SNP forms a synergistic effect (Chapter III Scheme 1) that improves 
the coagulant ability significantly over bare SNPs.(135) The polyP-SNP’s ability to stimulate 
the intrinsic and common pathways in patients with life-threatening bleeding might be a 
viable alternative to what is currently available in management of these patients. The long-
term stability of the polyP-SNP system at ambient conditions(135) could allow for 
prehospital use. Minimizing the time between injury and treatment may enable the body to 
successfully generate and maintain healthy clots prior to or upon initial onset of ATC.(151, 
152)  
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Scheme 3. To be an ideal clotting agent, polyP-SNP must enable clotting even in the face 
of the lethal triad - coagulopathy, hypothermia, and acidosis. Diagram courtesy of Dr. 
Anna May-Masnou. 
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B. Materials, Synthesis of silica nanoparticles and polyphosphate coated silica 
nanoparticles, Clotting assays 
Both the Materials, Synthesis, and Clotting sections of this chapter are identical to the 
sections published in the previous chapter (Chapter III).  
C. Modification of plasma  
1. Hemodilution 
Pooled normal plasma (PNP) was stored at -80oC and thawed less than 1 h before 
conducting the assay. Iatrogenic coagulopathy was reproduced in vitro through hemodilution 
with isotonic saline or phosphate buffered saline solution to reach the desired dilution level – 
i.e., 100 µl saline added to 300 µl PNP produced 400 µl 75 % plasma. 100 %, 75 %, 50 %, 
40 %, 33 %, and 25 % PNP levels were tested. 
 2. Hypothermia 
Hypothermia was induced through temperature variation: 37 °C, 35 °C, 32 °C, and 30 °C. 
Plasma was incubated at the desired temperature for 20 min prior to conducting the assay. 
Both instruments (thromboelastograph and plate reader) used had temperature settings. Prior 
to the assay, temperature on the instrument was set at the desired temperature (e.g., 32 °C for 
moderate hypothermia) prior to the experiment. This ensured that the reaction took place at 
the desired temperature and that the plasma did not warm up to 37 °C during the course of 
the assay. 
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 3. Acidosis 
PNP was acidified using lactic acid. Because PNP was purchased from George King 
Biomedical instead of procured fresh, I determined to use base deficit or acid excess as the 
marker for acidosis instead of pH for my studies. Base deficit – the amount of base required 
to counteract the acid in blood - is an excepted clinical marker for acidosis.(32) 2 mmol lactic 
acid/L, 5 mmol lactic acid/L, and 10 mmol lactic acid/L blood plasma were tested. 
D. Discussion 
In previous studies, I have illustrated the efficacy of polyP-SNP under non-traumatic 
conditions.(135)  Using ~70 nm SNPs as the core for polyP functionalization, I compare the 
effectiveness of the polyP-SNP system to that of known initiators of blood clotting: bare SNP 
and lipidated tissue factor (LTF). Plasma was modified to simulate the lethal triad. Clotting 
activity was determined by two different methods: thrombin activity using a thrombin-
specific fluorescent dye and thromboelastography (TEG). Coagulation was assessed both by 
the production of the key protein (thrombin) as well as development of the clot from its 
inception through full clot size (TEG). The data given below show that polyP-SNP retains its 
clotting function even under critical conditions, where other pieces of the clotting cascade 
cease to function.  
My focus on coagulopathy was due to its presence in the severely injured trauma 
population as well as its ties to worsening outcomes. Having previously identified 0.25 
mg/ml as the ideal polyP-SNP concentration,(135) I tested this concentration of polyP-SNP 
against the LTF and SNP baselines.  Due to the loss of both procoagulant and anticoagulant 
factors, prior research suggested hemodilution only begins to inhibit clotting locally at the 50 
% level.(144) Using TEG (Figure 46) and thrombin generation tests (Figure 56), I established 
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a dilution baseline in line with the findings of Herrmann et al. using the body’s main defense 
against vessel injury, lipidated tissue factor (LTF) as well as bare SNPs. The baseline 
confirmed that clot time and thrombin formation decreased below the 50 % threshold. As the 
plasma become more dilute, all factor levels, especially fibrinogen, dropped. As a result, 
using the same clotting agent (polyP-SNP, Figure 6), clot time decreased slowly while both 
clot acceleration and clot size decreased significantly. 
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Scheme 4. ATC mainly inhibits coagulation through hyperfibrinolysis, preventing the 
formation of stable and healthy clots to stop bleeding as well as lowering the 
concentration of fibrinogen, the protein that supplies fibrin for the clot. 
 
  
 118 
 
 
Figure 46. TEG clot time for several agents based on PNP hemodilution. PolyP-SNP 
outperforms all agents regardless of plasma hemodilution. 
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Figure 47. Actual TEG curve showing all three agents at 50 % hemodilution. PolyP-
SNP has quickest clot time, largest rate of clot growth, and peak clot size. 
  
 120 
 
 
Figure 48. As the factor concentrations decrease in hemodilute plasma (e.g., 40 % is 40 
% PNP and 60 % dilutant), clot time decreases slightly and the clot growth rate and 
overall clot size both decrease significantly even when polyP-SNP is used. 
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Furthermore, the TEG curve (Figure 47) shows that polyP-SNP also accelerated clot 
growth to reach a maximum clot size faster than the other agents. PolyP-SNP’s ability to 
quickly grow clots is extremely valuable given Hagemo et al.’s findings that fibrinogen 
levels and fibrin clot size after 5 minutes were the best predictors of coagulopathy and need 
for massive transfusion in trauma patients.(153) While polyP-SNP cannot counteract 
decreases in fibrinogen levels, the accelerated clot growth suggests that polyP-SNP can help 
convert more fibrinogen into the fibrin needed for the physical clot. Overall, these data 
suggest that quicker intervention during blood loss should improve clotting function, which 
could prevent or help mitigate the effects of coagulopathy. 
After testing polyP-SNP on hemodilution, my next tests focused on hypothermic and 
acidotic plasma. The TEG was set to hypothermic conditions to ensure that the plasma did 
not reach normal body temperature during the assay. At moderate to severe hypothermia, 32 
°C and 30 °C, both SNPs, and LTF showed significant prolongation in TEG clot time, with 
LTF clot times rising above 4 min (Figures 50, 51). The loss of clotting ability by LTF may 
be explained by Ramaker et al.’s theory, which states that reduced body temperature results 
in decreased rate kinetics of many of the coagulation factors, especially formation of the 
tissue factor-FVIIa complex.(145) Decreasing temperature did not significantly alter clot 
time or overall clot size, but it did slow the rate of clot formation (Figures 50, 51). 
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Scheme 5. Hypothermia primarily impairs coagulation by slowing activation of the 
TF_FVIIa complex, the mechanism by which the extrinsic pathway initiates clotting. 
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Figure 49. TEG clot time for hypothermic plasma. PolyP-SNP is superior to both LTF 
and bare SNP. 
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Figure 50. Actual TEG curve comparing all three agents at 32 °C or moderate 
hypothermia and 10 mmol/L lactic acid. 
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Figure 51. As temperature decreases, clot time remains stable, but rate of clot growth 
and final clot size decrease even when polyP-SNP is used. 
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Scheme 6. Acidosis primarily impairs thrombin generation, the main pathway by which 
polyP-SNP drives coagulation. 
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Figure 52. TEG clot time for acidified plasma. PolyP-SNP is superior to both LTF and 
bare SNP. 
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Figure 53. Actual TEG curves comparing all three agents at acidotic (10 mmol lactic 
acid/L blood plasma) conditions. 
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Figure 54. As more lactic acid is added, clot time, rate of growth, and final size all 
decrease even when polyP-SNP is used. 
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Acidosis was achieved through the addition of excess lactic acid to simulate metabolic 
acidosis.(36) Acidosis is treated clinically through the administration of sodium bicarbonate, 
though it can take 24 h after neutralization for the effects of acidosis to abate.(147) I chose to 
measure acidosis as the amount of excess lactic acid in the solution because the time between 
blood draw and assays was too long for an acceptable pH measurement. Of the triad, acidosis 
has the greatest effect on thrombin generation,(147) which can lead to exsanguination if 
unchecked. Because it accelerates coagulation through increased thrombin production, 
acidosis had a greater effect on polyP-SNP (Figure 52 - 54, 58) than the rest of the triad. 
However, even in the presence of 10 mmol/L excess lactic acid, polyP-SNP still 
outperformed LTF and SNP in generating thrombin and clots. 
Thrombin production is the key role of the common pathway and accelerates growth of 
the nascent clot. Under all conditions, polyP-SNP outperformed bare SNP and LTF in 
producing thrombin. At 50 % hemodilution, the thrombin burst occurred roughly 100 
seconds quicker for polyP-SNP than bare SNP and even later for that of LTF (Figure 55). 
More significantly, LTF was unable to generate significant thrombin below 33 % dilution of 
plasma. This suggests that there is a blood-loss threshold at which the body alone fails to 
adequately produce the thrombin required for significant, healthy clots. In comparison, 
polyP-SNP significantly hastens thrombin formation to accelerate clot formation under all 
hemodilutional conditions. 
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Figure 55. At 50 % PNP hemodilution, polyP-SNP generates thrombin much faster 
when compared to LTF and bare SNPs. 
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Figure 56. Under increasing hemodilution (33 % PNP), polyP-SNP generates thrombin 
quickly even when LTF cannot. 
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As stated by Ramaker, hypothermia leads to a decreased kinetic rate of factor 
activation.(145) Unlike the coagulopathy simulation, the decrease in activity did not result in 
complete inhibition of thrombin production. In comparison, polyP-SNP’s effect on thrombin 
production barely decreased, reaching peak thrombin generation at around 2 min under 
severe hypothermia. When the plasma was chilled to moderate hypothermia, 32 °C, polyP-
SNP generated maximum thrombin fluorescence around 1 min, while LTF did not reach 
maximum thrombin production until 10 min (Figure  58). These data suggest that the polyP-
SNP system adjusts to temperature loss better than the clot initiation pathways alone. As 
described by Martini et al., thrombin production was significantly impaired by excess lactic 
acid. Yet even at a concentration of 10 mmol/ L excess lactic acid (Figure 58), polyP-SNP’s 
still outperformed LTF and SNP. 
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Figure 57. At 32oC, polyP-SNPs generate thrombin at an accelerated rate compared to 
LTF or bare SNPs. 
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Figure 58. Though excess lactic acid delays thrombin production, polyP-SNP minimizes 
the time to thrombin burst. 
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The data produced suggests a first step at developing a novel clotting agent. However, 
ATC is a multifactorial process involving an endogenous hypocoagulable state occurring 
nearly immediately after injury complicated by issues such as the injury suffered, clotting 
abnormalities, cellular interaction, and inflammation.(33) Along with ATC, the onset of an 
iatrogenic coagulopathy resulting from dilution, hypothermia, and acidosis is a key factor in 
mortality relating to trauma-induced hemorrhage. The in vitro data produced mimics the 
lethal triad that complicates treatment. However, in vivo trials will be required to adequately 
reproduce ATC conditions.(34) In addition to injury models for effectiveness, in vivo trials 
will also determine if the polyP-SNP system is as safe as theorized through pharmacokinetic 
and pharmacodynamic studies. 
E. Conclusion 
Stopping bleeding and correcting coagulopathy remain the key goals in trauma treatment. 
Rapid effectiveness of both is the key to saving lives and preventing morbidity. PolyP-SNPs 
are effective, stable at ambient conditions, and far cheaper than recombinant proteins. 
Attaching polyP to the shell of SNPs significantly reduces clot time and time to thrombin 
burst despite severe drops in factor levels, temperature, or pH. PolyP-SNP particles may have 
the ability to serve as a new type of agent for hemorrhage intervention based on its potential 
to drive coagulation in critical conditions. Further exploration of polyP-SNP’s ability to limit 
contact activation in vivo will be necessary for use as a systemic agent. Ultimately, in vivo 
trials(34) will determine whether stable, intravenous polyP-SNP will allow emergency 
medical personnel to stabilize a patient’s clotting function either before or much sooner after 
the onset of coagulopathy, thereby preventing massive blood loss and lead to greater patient 
outcomes upon hospital admission.  
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V. Future work 
The Guide and I into that hidden road 
Now entered, to return to the bright world; 
And without care of having any rest 
 
We mounted up, he first and I the second, 
Till I beheld through a round aperture 
Some of the beauteous things that Heaven doth  
bear; 
Thence we came forth to rebehold the stars. 
- Dante Aligheiri, Inferno, Canto XXXIV, 133-139 
A. Introduction  
There is no ideal hemostatic agent. Even worse there is a lack of intravenous clotting 
agents to treat the most dangerous wounds. Clinicians have rapidly increased their 
knowledge of trauma to understand how the body becomes coagulopathic after shock and 
injury. As modeling becomes more adept, medical personnel will be able to predict which 
patients will become coagulopathic, leading to improved immediate care for patients and 
decreasing mortality rates. 
A recent trend in coagulopathy has been the development of different treatments for 
different conditions. External injuries are treated with tourniquets and topical devices to 
quickly stop the flow of blood. ATC bleeding is now primarily treated with TXA or PCC.(8, 
127) Patients with genetically-impaired clotting cascades, such as hemophiliacs, who bleed 
receive rFVIIa.(154) If the patient is on the vitamin K anticoagulant Coumadin, PCC will be 
administered.(83) If the patient is on a novel oral anticoagulant (NOAC), there is no currently 
indicated treatment.(155) 
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B. Translating research from the benchtop to clinical use 
While polyP-SNP’s are attractive based for their improved clotting performance in vitro, 
this is only the first step in a long, arduous process of drug development. This process begins 
with drug discovery in labs, graduates to preclinical trials in simple and complex mammalian 
systems, and, finally, leads to clinical trials (Figure 59). While preclinical trials are a 
requirement for clinical application, animal models are not ideal predictors of ATC in 
humans. In a recent study, 43 animal models (30 swine, 6 rabbit, 5 rat, 1 sheep, 1 mouse, and 
0 primate) were compared and none were considered to fully encompass the multiple systems 
that play a role in ATC.(34) Researchers will likely continue to rely upon swine for injury 
models because swine have the most similar (pro)coagulation cascade to humans.(156)    
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Figure 59. Translation of potential clotting drugs into clinical trials. After drug 
discovery, potential clotting agents are tested first in rats for proof of concept of safety 
and efficacy. Swine are used for the complex mammalian model because the circulatory 
system is similar to that of humans. If successful, the FDA approves the drug as an 
Investigational New Drug (IND) for use in clinical trials.  
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A pilot study using Sprague-Dawley rats was initiated in collaboration with Chi Nguyen 
of Galen Stucky’s lab (UCSB Chemistry) and Kyle Ploense of Tod Kippin’s lab (UCSB 
Psychology and Brain Sciences). Particles were suspended in saline and injected into healthy 
rats at a maximum concentration of 2 mg / kg body weight. Blood was drawn at specific time 
points and tested using TEG to determine clot time and clot size (Figure 60). The animals 
were euthanized after 3 hours. Chi Nguyen conducted the post-euthanasia analysis using 
ICP-MS to track particle accumulation in major organs (Figure 61). In addition, samples 
were sent to Charles River Laboratories (Wilmington, MA) to test for evidence of 
thrombosis. Tests results indicated no positive evidence of thrombosis. It is important to 
stress that these initial results are extremely preliminary and not conclusive. Further trials 
must be conducted to build a significant population.  
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Figure 60. 2 mg / kg polyP-SNP lowers clot time on blood drawn from a Sprague-
Dawley rat between roughly 40 -80 minutes after injection. Time 0 corresponds to blood 
drawn prior to polyP-SNP injection. Trial conducted with Chi Nguyen (Stucky lab) and 
Kyle Ploense (Kippin lab). 
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Figure 61. 2 mg / kg polyP-SNP increases maximum clot size increases after injection in 
Sprague-Dawley rat. Trial conducted with Chi Nguyen (Stucky lab) and Kyle Ploense 
(Kippin lab). 
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C. Barriers to translation 
1. Complement activation related pseudoallergy (CARPA) 
Beginning with cancer treatments,(119) the study of nanoparticles for drug delivery use 
has increased dramatically in the last decade. Nanomedicine has the potential to provide 
improved stability,(135) imaging,(157) and targeting(158) to improve treatment for a myriad 
of conditions. One of the greatest risks with nanomedicine has been the development of a 
complement activation related pseudoallergy (CARPA). CARPA includes, but is not limited 
to, cardiopulmonary, hemodynamic, hematological, biochemical and dermatological changes 
in the patient that present within minutes of injection (Figure 62).(159) While most 
symptoms dissipate quickly, CARPA can lead to death on its own.(160) In trauma patients, 
CARPA can accentuate the inflammatory response related to injury, disrupt normal 
coagulation cascades, and alter hemodynamics.(161) ~10 % of patients have a reaction to 
doxorubicin and other nanomedicine chemotherapeutics, even when drugs are coated with 
polyethylene glycol (PEG, PEGylated) and infused slowly.(162) The particle’s surface 
charge, size, and the particle make-up can all increase a patient’s chances at hyper-
sensitivity. 
CARPA is defined best as a set of symptoms rather than a specific syndrome. CARPA 
does not affect small mammals such as rodents and mice, the traditional first step in drug 
discovery. However, Szebeni et al. have identified that swine and canine models are the most 
effective animal models for predicting CARPA in humans.(159) While primates remain the 
closest human analogue, non-human primate CARPA models have not been developed. 
Research is required to determine the pathogenesis of CARPA. This research must begin 
with more complex mammalian models to study systems that are affected by this condition. 
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Figure 62. Symptoms seen in a CARPA swine model. Reprinted from Advanced Drug 
Delivery Reviews, Vol 64, Issue 15, J Szebeni, P Bedocs, D Csukas, L Rosivali, R 
Bunger, R Urbanics, A porcine model of complement-mediated infusion reactions to 
drug carrier nanosystems and other medicines, 1706-1716, Copyright (2012), with 
permission from Elsevier.(159)   
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D. Anticoagulant reversal  
Warfarin, a Vitamin K antagonist, is the most widely prescribed oral anticoagulant drug 
in America. Warfarin acts to prevent activation of multiple proteins tied to clotting including 
procoagulant F(actors) X, VII, and II (thrombin) and the anticoagulant protein C. As a result, 
patients receiving warfarin often suffer from serious side effects, including adverse 
interactions with a myriad of food and drugs. Patients suffering minor injuries on warfarin 
can develop uncontrollable hemorrhage. In cases of bleeding, both Vitamin K and 
prothrombin complex concentrate are FDA-approved antidotes to reverse the effects of 
warfarin.(163)  
Two new classes of anticoagulants have been developed to minimize the side effects seen 
in warfarin. These single factor inhibitors prevent activation of FXa (rivaroxaban) or 
thrombin (argatroban). Since FDA approval in 2011, doctors have prescribed rivaroxaban 
over 6 million times.2  In 2012 alone, there were over 30 million chronic prescriptions for 
warfarin. Hindering further usage, single-factor inhibitors lack an approved antidote.(164)  
Recently, recombinant FXa has been shown to be a potential antidote for rivaroxaban.(163) 
Even if it is effective, recombinant FXa will suffer from the same cost and storage issues that 
all recombinant proteins face.  
In addition to its effect on coagulation, short-chain polyP has also been shown to 
effectively reverse both genetically and medically induced coagulopathy, including the 
NOACs rivaroxaban and argatroban (Figure 63).(131) While this has not been confirmed in 
the polyP-SNP system, polyP-SNP increases thrombin production tenfold over bare 
polyP(165) and, thus, should be effective at overcoming anticoagulation in the event of the 
                                                 
2 Data provided by Janssen Pharmaceuticals, Inc. 
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bleed. PolyP-SNP’s easiest path to clinical use may follow the track of PCC: FDA approval 
as an anticoagulant reversal agent with the potential to also mediate ATC-related 
hemorrhage. When combined with SNP, polyP has the long-term stability and cost-
effectiveness of a topical agent combined with the in vitro effectiveness of a recombinant 
protein. If polyP-SNP can be shown to be safe and effective in vivo, this therapeutic could 
lead to a breakthrough in trauma management by increasing the trauma population that is 
able to be treated prehospital, significantly decreasing the time between injury and first-
treatment that is critical to patient survival. 
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Figure 63. PolyP (black) lowers clot time for the anticoagulants (A) heparin, (B) 
enoxaparin, (C) NOAC argatroban, and (D) NOAC rivaroxaban. Reprinted from 
Journal of Thrombosis and Haemostasis, Vol. 6, Issue 10, SA Smith, JH Morrissey, 
Polyphosphate as a general procoagulant agent, 1750-1756, Copyright (2008), with 
permission from John Wiley and Sons. (131) 
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 While this thesis covers only the drug discovery stage, the results presented within 
show the exciting potential of the polyP-SNP system. In all in vitro assays, polyP-SNP 
proved an excellent agent at inducing coagulation. The next step is to translate this research 
into preclinical trials to determine if polyP-SNP is indeed safe and effective in the face of 
systematic hemostatic damage. If successful, polyP-SNP has the potential to act as an ideal 
universal procoagulant, able to accelerate clotting in traumatic injuries regardless of current 
problems such as the patient’s condition, injury locus, and inability to rapidly transport the 
patient to a medical facility. Humans will never eradicate injury, but, with improved 
knowledge and smarter therapeutics, the damage can be mitigated. 
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